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While risk scores are invaluable tools for adapted preventive strategies, a signiﬁcant gap exists between
predicted and actual event rates. Additional tools to further stratify the risk of patients at an individual
level are biomarkers. A surrogate endpoint is a biomarker that is intended as a substitute for a clinical
endpoint. In order to be considered as a surrogate endpoint of cardiovascular events, a biomarker should
satisfy several criteria, such as proof of concept, prospective validation, incremental value, clinical utility,
clinical outcomes, cost-effectiveness, ease of use, methodological consensus, and reference values. We
scrutinized the role of peripheral (i.e. not related to coronary circulation) noninvasive vascular bio-
markers for primary and secondary cardiovascular disease prevention. Most of the biomarkers examined
ﬁt within the concept of early vascular aging. Biomarkers that fulﬁll most of the criteria and, therefore,
are close to being considered a clinical surrogate endpoint are carotid ultrasonography, ankle-brachial
index and carotid-femoral pulse wave velocity; biomarkers that fulﬁll some, but not all of the criteria are
brachial ankle pulse wave velocity, central haemodynamics/wave reﬂections and C-reactive protein;
biomarkers that do no not at present fulﬁll essential criteria are ﬂow-mediated dilation, endothelial
peripheral arterial tonometry, oxidized LDL and dysfunctional HDL. Nevertheless, it is still unclear
whether a speciﬁc vascular biomarker is overly superior. A prospective study in which all vascular
biomarkers are measured is still lacking. In selected cases, the combined assessment of more than one
biomarker may be required.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Accurate assessment of cardiovascular (CV) risk is essential for
clinical decision-making; the beneﬁts, risks and costs of manage-
ment strategies must be weighed to choose the best individually
tailored preventive strategy. Many scores have been developed over
the years to classify patients into low, medium or high CV risk
groups. In Europe, the HeartScore and its online version, Systemic
Coronary Risk Evaluation (SCORE), have been introduced for the
prediction of the total fatal 10-year CV risk [1]. In the U.S.A., a
number of different risk scores have been validated. The most
widely used ones come from the Framingham Heart Study group
that has proposed an array of 14 risk equations [2], while the most
recently proposed risk equation by the American College of Cardi-
ology/American Heart Association (ACC/AHA) [3] has been the
subject of controversy.
Risk scores are not, however, ﬂawless and their head-to-head
comparison opens many questions [4]. Moreover, a small, yet sig-
niﬁcant gap exists between predicted and actual event rates,
leading to under- and over-prediction, thus raising the issue of
calibration. The extrapolation to populations different from the
original cohort, the choice of traditional risk factors that are
included, the changes in population characteristics because of the
time delay between observational studies and application of
risk scores, as well as the omission of novel indices relating to
CV pathophysiology may partly explain the limitations of risk
scores [5].
Additional tools to further stratify the risk of patients are
biomarkers. According to the National Institutes of Health deﬁ-
nition, a biomarker is “a characteristic that is objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic responses to a
therapeutic intervention” [6]. In essence, and in the setting of
prevention, CV biomarkers reﬂect early functional or morpho-
logical changes, well before overt disease manifests. This iden-
tiﬁcation of subclinical disease may open a window of
opportunity to prevent the occurrence of clinical CV disease by
timely treatment.
Vascular biomarkers as surrogate endpoints:
A surrogate endpoint is a biomarker that is intended as asubstitute for a clinical endpoint. Changes in surrogate endpoints
are detected earlier and at a lower cost than clinical endpoints (e.g.
morbidity and mortality). Thus, diagnosis and clinical trials are
facilitated. A surrogate endpoint is expected to predict clinical
beneﬁt/harm or lack thereof, based on epidemiologic, therapeutic,
pathophysiological or other scientiﬁc evidence. In order to be
considered as a “surrogate endpoint” of CV events, a biomarker
should satisfy several steps. According to the AHA, the 6 phases of
evaluation of a novel risk marker include: 1. Proof of concept: Do
novel biomarker levels differ between subjects with and without
outcome? 2. Prospective validation: Does the novel biomarker
predict development of future outcomes in a prospective cohort or
nested case-cohort study? 3. Incremental value: Does it add pre-
dictive information over and above established, standard risk
markers? 4. Clinical utility: Does it change predicted risk sufﬁ-
ciently to change recommended therapy? 5. Clinical outcomes:
Does the use of the novel biomarker improve clinical outcomes,
especially when tested in a randomized clinical trial? 6. Cost-
effectiveness: Does the use of the biomarker improve clinical out-
comes sufﬁciently to justify the additional costs? [7].
On top of the aforementioned criteria, a biomarker should be
relatively easy tomeasure, in a non-invasive manner, according to a
well-deﬁned protocol and the obtained metric should distinguish
individuals at risk, in order to be deemed suitable for use in clinical
practice. Therefore, 3 additional steps (not present in the AHA
scientiﬁc statement) [7] should be added in the assessment of
vascular biomarkers to qualify as clinical surrogate endpoints: 7.
Ease of use: this will allow widespread application, 8. Methodo-
logical consensus: necessary to allow comparisons between studies
and 9. Reference values: or, at least, cut-off values.
Fulﬁlment of the 9-step criteria for each vascular biomarker
(Table 1) will be subsequently discussed in relevant sections.
Though all have a sound proof of concept and have been prospec-
tively validated (steps 1 and 2), the incremental value, clinical
utility and clinical outcomes (steps 3e5) have only been estab-
lished for few of them; cost-effectiveness data (step 6) are almost
uniformly lacking. The majority of them are easily measured (step
7), methodological consensus (step 8) has been reached for some,
yet reference values (step 9) exist for only a few vascular
biomarkers.
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concept of early vascular aging. According to this concept, a cu-
mulative measure of the impact of CV risk factors on the arterial
wall, in association and interaction the individual genetic back-
ground, has the potential to accurately gauge a person's overall CV
risk [8]. The aim of this document is to scrutinize the role of pe-
ripheral (i.e. not related to coronary circulation) noninvasive
vascular biomarkers for primary and secondary CV disease pre-
vention. The most widely used biomarkers related to vascular
structure and function are presented; a uniform approach has been
followed, including a brief methodological presentation, the cur-
rent role, potential use as a surrogate endpoint, advantages/dis-
advantages and future perspectives. Regarding the order of
presentation, the date of publication of the ﬁrst outcome study for
each vascular biomarker was used; those with the oldest outcome
studies are presented ﬁrst. The role of vascular biomarkers in the
setting of comorbidities is presented, as well as their potential for
guiding treatment. The Tables, as well as a dedicated section of the
document provide detailed comparisons between vascular bio-
markers at a glance; these should help clinicians in selecting the
appropriate index to be measured in different clinical and research
scenarios.
2. Carotid ultrasonography
Usefulness for primary and secondary CV disease prevention
(Recommendation/Level of evidence): IIa/A.
Inﬁltration of the subintimal layer of arteries by lipids and in-
ﬂammatory cells constitutes an early process in the atherosclerotic
continuum. Imaging techniques with adequate spatial resolution
can assist in the timely detection and quantiﬁcation of structural
changes in the arterial wall that are associated with atheroma,
ﬁbrosis and the aging process. A thick intima-media complex, and
carotid plaque as its extreme manifestation, serves as a proxy of
generalized atherosclerosis. Though often regarded as two distinct
phenotypes and biomarkers with different usefulness for risk pre-
diction, both carotid intima-media thickness (cIMT) and plaque
presence are assessed during imaging and provide complementary
prognostic information, thus they cannot be viewed in isolation.
The most commonly and easily accessed site is the common carotid
artery and its bifurcation, though the femoral artery has also been
studied.
Methodology:
cIMT is measured with transcutaneous ultrasound in B-mode
images of the carotid tree as the distance of the intimal to the
adventitial layer (visible as a typical double line of the arterial wall).
cIMT is measured most easily in the segment of the distal common
carotid artery based on the Mannheim consensus [9], but risk
prediction should be based on a thorough scan of the carotid ar-
teries to detect the presence of plaques and on the measurement of
the cIMT of the common carotid artery [10]. The intra- and inter-
observer agreement, as well as the accuracy of measurements ofTable 1
Criteria for vascular biomarkers to qualify as clinical surrogate endpoints.
1 Proof of concept Do novel biomarker levels differ betwe
2 Prospective validation Does the novel biomarker predict deve
3 Incremental value Does it add predictive information over
4 Clinical utility Does it change predicted risk sufﬁcient
5 Clinical outcomes Does the use of the novel biomarker im
6 Cost-effectiveness Does the use of the biomarker improve
7 Ease of use Is it easy to use, allowing widespread a
8 Methodological consensus Is the biomarker measured uniformly in
9 Reference values (or cut-off values) Are there published reference values, o
Modiﬁed from: Hlatky et al. Circulation 2009. Criteria 7e9 constitute additional essentiathe mean cIMT was found to be highest in the common carotid
artery, followed by the carotid bifurcation and inner carotid artery
[11e15]. The optimal reproducibility obtained by scanning the
common carotid artery is due to the ease of acquiring good quality
images at an insoniﬁcation angle of 90; this, however, comes at the
cost of missing disease thatmore often develops at the carotid bulb/
internal carotid artery [16]. Reading should be done with semi-
automated reading software (better than automated) [17] over a
1-cm segment because of the ease of use, potential to improve
ultrasound quality, and probably lower variability compared to
manual measurements [15,18,19]. An alternative method with
better spatial and temporal resolution is the measurement of cIMT
using echo-tracking [20], however, a possible advantage of B-mode
based analysis is that it can be easily used with standard high-
resolution ultrasound equipment. The reproducibility of echo-
tracking and B-mode based measurement of cIMT was shown to
be similar in patients with increased risk factor burden and/or
manifest atherosclerotic disease [21,22]. A value above the 75th
percentile of a reference population is generally accepted as a
threshold for increased cIMT [10]. A value of 0.9 mm is set as a cut-
off in the European Society of Cardiology (ESC) guidelines [23,24];
this simpliﬁcation may, however, lead to misclassiﬁcation in
different populations and age groups where similar values may be
within the normal range [25].
Carotid plaque may represent a later stage or a different
phenotype of atherosclerosis than increased cIMT [9,26]. However,
this cannot be differentiated by ultrasound; many studies do not
discriminate between plaque or cIMT and incorporate plaque
thickness into cIMT measurements [27]. As a consequence,
maximum cIMT (in contrast to mean cIMT) is close to plaque
thickness if the Mannheim consensus is not used and cIMT is
considered as a continuous parameter; this causes some confusion
in the interpretation of the studies. Carotid plaque may be
measured with ultrasound in 2D and in 3D-images. Several char-
acteristics of plaques are currently examined, like the dissemina-
tion within the carotid tree, echogenicity (echolucent, echogenic,
mixed echogenicity), echogenic distribution pattern (homogeneous
versus inhomogeneous) and evaluation of surface structure (regu-
lar versus irregular [28]). Recently, plaque vascularization on
contrast-enhanced ultrasound has been developed to optimize
cardiovascular risk prediction [29]. Among these plaque charac-
teristics, total plaque volume was the most commonly evaluated
parameter showing good inter- and intra-observer reproducibility
(>90%) [28,30]. However, it is unclear whether different 3D tech-
niques could be sufﬁciently standardized between laboratories,
thus allowing widespread clinical usage [27]. Robust data upon
superiority of 3D ultrasound over 2D is pending [28]. At present,
the assessment of carotid plaque in population studies is mainly
done in B-mode images of the carotid tree. In the clinical setting,
easy to assess and reproducible plaque-based parameters (presence
vs. absence or number of plaques), and simple deﬁnitions (plaque:
maximum cIMT >1.5 mm) are advocated [31]. At the moment, noen subjects with and without outcome?
lopment of future outcomes in a prospective cohort or nested case-cohort study?
and above established, standard risk markers?
ly to change recommended therapy?
prove clinical outcomes, especially when tested in a randomized clinical trial?
clinical outcomes sufﬁciently to justify the additional costs?
pplication?
different laboratories? Are study results directly comparable?
r, at least, cut-off values?
l criteria to the original criteria 1e6 proposed by Hlatky and coworkers [7].
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guidelines.
Fulﬁlment of surrogate endpoint criteria:
1. Proof of concept:
cIMT:Multiple studies e by far more than for any other imaging
biomarker - have shown higher cIMT in subjects with higher risk
factor burden or manifest atherosclerotic disease [9].
Carotid plaque: A similar relation is true for carotid plaque but
in a far lower number of publications [27,31] (Table 2).
2. Prospective validation and 3. Incremental value:
cIMT: The prediction of future outcomes in prospective cohorts
has been proved in several studies (Table 3). A meta-analysis of 16
studies with 36,984 participants showed an increase in risk for
future CV events of 16% per 0.1 mmdifference in baseline cIMT [32].
A recent meta-analysis based on data from 14 cohort studies
(45,828 individuals from the general population) showed that
common cIMT measurements do not add signiﬁcantly to the Fra-
mingham Risk Score (FRS) regarding the prediction of ﬁrst-time
myocardial infarction or stroke [33]. Another study did not show
any predictive value of common cIMT measurement in subjects
with diabetes mellitus [34]. However, it should be mentioned that
this holds true only for common cIMT. Data for carotid bifurcation
and internal cIMT have not been analysed so far. Furthermore,
different deﬁnitions of the common carotid segment and tracing
methods might have weakened the power of the analysis; in
addition, the study population consisted mainly of Caucasian in-
dividuals, so results cannot be extrapolated to other ethnicities.
Carotid plaque: Carotid plaque confers a superior diagnostic
accuracy for future myocardial infarction compared to cIMT ac-
cording to a recent meta-analysis (n ¼ 54,336) [27] and this was
corroborated by a systematic review [35]. The presence of carotid
plaques predicted CV mortality independently of the SCORE strat-
iﬁcation and increased the risk for CV death by 2e4 times in in-
termediate risk and low risk individuals, respectively [36]. An
incremental CV disease risk prediction with increasing number of
plaques (1 site ¼ 1.5; 95% conﬁdence interval [CI]: 1.0e2.2; 2
sites ¼ 2.2; 95% CI: 1.6e3.1), but not with increasing cIMT has been
shown in the Three-City Study [37]. In the Atherosclerosis Risk In
Communities (ARIC) study, both cIMT and presence of plaque
contributed to improved CV disease risk prediction [38]. Similarly,
ultrasound-derived plaque metrics improved risk prediction in the
Multiethnic Study of Atherosclerosis (MESA) cohort [31]. In general,
studies on carotid plaque are in smaller cohorts than those on cIMT;
similarly, they consist of Caucasians mostly, so again results cannot
be extrapolated to other ethnicities.
4. Clinical utility:Table 2
Sensitivity to detect changes and guide for pharmacological treatment.
Guide for
pharmacological
therapy
Carotid ultrasonography þþ
Ankle-brachial index þþ
Arterial stiffness
Carotid-femoral pulse wave velocity þþþ
Brachial-ankle pulse wave velocity þþ
Central haemodynamics/Wave reﬂections þþþ
Endothelial function
Flow mediated dilatation þþþ
Endothelial peripheral arterial tonometry þ
Circulating biomarkers related to vascular wall biology
High sensitivity C- reactive protein þþþcIMT: The meta-analysis by Den Ruijter et al. demonstrated that
cIMT had a small, yet signiﬁcant potential for reclassiﬁcation only in
intermediate risk individuals, with a clinical net reclassiﬁcation
index (NRI) of 3.2% in men and 3.9% in women (overall NRI: 0.8%),
with a wide range among studies [33]. Given the small reclassiﬁ-
cation potential of cIMT, which is only evident in intermediate risk
individuals, its clinical utility is open to question.
Carotid plaque: In contrast to cIMT, studies that include
assessment of plaque in general improve reclassiﬁcation; the NRI
for plaque presence was slightly higher and ranged from 5.6% for
individuals with prior CV disease to 8.1% for individuals without CV
disease at baseline [37]. In the MESA cohort, cIMT plus plaque
together resulted in an overall NRI of 9.9%; when only intermediate
risk subjects were considered, the clinical NRI was 21.7% [31].
Similar results were reported from the Framingham Offspring
Study cohort and a large Chinese population [39,40] (Table 3).
5. Clinical outcomes: The question if a cIMT-driven therapy
leads to better outcomes has not been answered yet. In practice,
high cIMT values and/or presence of plaque are considered as target
organ damage and call for aggressive risk factor modiﬁcation.
Though there are no studies to support such practices, carotid ul-
trasound scanning for detection of increased cIMTor carotid plaque
may lead to increased prescription of aspirin and statins by physi-
cians [41] and intensiﬁed goal setting for LDL-cholesterol levels
[42]. However, conﬂicting results have been reported regarding the
impact of carotid ultrasound scanning on patient motivation
[41,43]. Lipid-lowering drugs can reduce carotid plaque volume
[44]; nevertheless, cIMT and plaque are biomarkers that change
slowly over time, therefore patients may be on optimal medical
therapy for a prolonged period of time and, yet, have increased
cIMT values and/or plaques. In spite of the aforementioned issues,
cIMT has been used as an intermediate endpoint in randomised
clinical trials of novel drugs [45]. Importantly, it has been demon-
strated that cIMT changes do not have prognostic implications; in a
large meta-analysis of 36,984 participants, cIMT progression was
not linked to future CV events [32].
6. Cost-effectiveness:
cIMT: One study simulated the cost-effectiveness of cIMT
screening over a 20e30 year period on the basis of the ARIC study
data using a Markov model [46]. Based on a 1% lower absolute risk
of myocardial infarction in men and of 1e3% lower risk in women
respectively, cIMT measurements increased quality-adjusted life
years (QALYs) by 0.01e0.02 in men and 0.03e0.05 in women. The
corresponding costs were an additional $100 per man, and a cost-
saving of $200e300 per woman.
Carotid plaque: No studies on cost-effectiveness forSensitivity for
changes
Time to
change
Prognostic value of changes
Low Slow No
Low No data Moderate
High Moderate Moderate
High Moderate No data
High Fast Good guide for therapy,
with the exception of
patients with heart failure and
a low ejection fraction
Very high Fast Moderate
Very high Fast No data
Moderate Fast No data
Table 3
Risk prediction improvement.
Study Outcome Markers added D C-statistica Overall net
reclassiﬁcation index
Clinical net
reclassiﬁcation
indexb
Reference
Carotid ultrasonography USE-IMT meta-analysis (n ¼ 45,828)
Framingham Offspring Study
(n ¼ 2965)
Prog-IMT meta-analysis (n ¼ 36,984)
Shijingshan district and Peking
University community cohort
(n ¼ 3258)
First time MI or stroke
Incident CVD
Future CV events
Future CV events
Common cIMT
Mean common cIMT,
maximum internal
cIMT, plaque presence
Mean common cIMT
Carotid plaque
0.757/ 0.759
Non-signiﬁcant for
mean common cIMT,
0.009 for maximum
internal cIMT, 0.014 for
plaque presence
e
0.742/ 0.751
0.8%
Non-signiﬁcant for
mean common cIMT,
7.6% for maximum
internal cIMT, 7.3% for
plaque presence
e
10.5%
3.6%
12.7% for
maximum
internal cIMT
e
e
Den Ruijter et al., 2012
Polak et al., 2011
Lorenz et al., 2012
Xie et al., 2011
Ankle-brachial index Multiethnic Study of Atherosclerosis
(n ¼ 1330)c
Ankle Brachial Index Collaboration
meta-analysis (n ¼ 48,294)
Incident CHD, CVD
Total mortality
ABI
ABI
0.623/ 0.650 (CHD),
0.623/ 0.650 (CVD)
0.646/ 0.655 (men),
0.605/ 0.658
(women)
3.6% (CHD), 6.8% (CVD)
e
3.6% (CHD),
6.8% (CVD)
Yeboah et al., 2012
Ankle Brachial Index
Collaboration 2008
Arterial stiffness
Carotid-femoral
pulse wave
velocity
Individual data meta-analysis
(n ¼ 17,635)
Meta-analysis (n ¼ 15,877)
Total/CV mortality, CV/
CHD events, stroke
Total/CV mortality, CV
events
Log (aortic PWV)
Carotid-femoral PWV
e
e
8.34% (CV mortality)
e
24.27% (CV
mortality)
e
Ben-Shlomo et al., 2013
Vlachopoulos et al., 2010
Brachial-ankle
pulse
wave velocity
Meta-analysis (n ¼ 8169) CV events Brachial-ankle PWV e e e Vlachopoulos et al., 2012
Central haemodynamics/
Wave reﬂections
Multiethnic Study of Atherosclerosis
(n ¼ 5960)
Taiwanese cohort (n ¼ 1272)
Meta-analysis (n ¼ 5648)
CV events
CV and all-cause
mortality
CV events
PPA, RM, AIx
Central systolic BP and
PP
AIx, central PP
0.002 (PPA), 0.002 (RM)
e
e
10% (PPA), 15% (RM)
e
e
e
e
e
Chirinos et al., 2012
Wang et al., 2009
Vlachopoulos et al., 2010
Endothelial function
Flow mediated
dilation
Meta-analysis (n ¼ 14,753)
Multiethnic Study of Atherosclerosis
(n ¼ 1330)c
Meta-analysis (n ¼ 5547)
Multiethnic Study of Atherosclerosis
(n ¼ 2843)
CV events
Incident CHD, CVD
CV events
Incident CV events
FMD
FMD
FMD
FMD
e
Non-signiﬁcant for
both CHD and CVD
e
Non-signiﬁcant
e
2.4% (CHD), 2.3% (CVD)
e
29%
e
2.4% (CHD),
2.3% (CVD)
e
28%
Ras et al., 2013
Yeboah et al., 2012
Inada et al., 2012
Yeboah et al., 2009
Endothelial
peripheral
arterial tonometry
Low-risk outpatients with chest pain
(n ¼ 270)
CV events Log (RHI) e e e Rubinshtein et al., 2010
Circulating biomarkers related to vascular wall biology
High sensitivity
C- reactive protein
Emerging Risk Factors Collaboration
meta-analysis (n ¼ 166,596)
Multiethnic Study of Atherosclerosis
(n ¼ 1330)c
First CV event
Incident CHD, CVD
Log (CRP), total and
HDL cholesterol
hsCRP
0.0039
0.623/ 0.640(CHD),
0.623/ 0.640 (CVD)
1.52%
7.9% (CHD), 3.7% (CVD)
e
7.9% (CHD),
3.7% (CVD)
Emerging Risk Factors
Collaboration 2012
Yeboah et al., 2012
ABI: ankle-brachial index; AIx: augmentation index; CHD, coronary heart disease; cIMT: carotid intima-media thickness; CV: cardiovascular; CVD, cardiovascular disease; FMD: ﬂow mediated dilation; HDL: high density
cholesterol; hsCRP: high sensitivity C-reactive protein; MI: myocardial infarction; PP: pulse pressure; PPA: pulse pressure ampliﬁcation; PWV: pulse wave velocity; RHI: reactive hyperemia index; RM: reﬂection magnitude; SD:
standard deviation.
a Change in C-statistic from addition of the novel marker to a classical risk factor model.
b Net reclassiﬁcation index calculated only for individuals at intermediate risk according to the Framingham Risk Score.
c Only individuals at intermediate risk for cardiovascular events, according to the Framingham Risk Score, were included from the original cohort; in this case the overall and clinical net reclassiﬁcation index are the same.
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7. Ease of use: Experienced sonographers are required for reli-
able image acquisition, especially for plaque detection. Automated
systems have facilitated cIMT measurements and 3D ultrasound
may help to quantify atherosclerotic plaque volume and
characteristics.
8. Methodological consensus: Strict standardization of ultra-
sound and reading protocols is required; the existing Mannheim
consensus [9], American Society of Echocardiography consensus
statement [10], and Prog-IMT procedures [32] are steps towards
standardization.
9. Reference values:
cIMT: Reference values for common cIMT measured with the
echotracking system have been reported [47].
Carotid plaque: Reference values for carotid plaque number,
volume and other characteristics are still lacking. It is still unclear if
the normal value should be “no carotid plaque”, as plaques are
frequently present in the elderly [25]. The concept of carotid plaque
burden, based on a 3D ultrasound approach, may constitute a better
metric of subclinical atherosclerosis [48e50].
Taken together, cIMT meets some of the 9 essential criteria to
classify as a clinical surrogate endpoint, whereas carotid plaque
meets most of them (Tables 4 and 5).
Advantages/disadvantages, issues remaining to be addressed
and future perspectives:
Carotid ultrasound allows the simultaneous assessment of both
cIMT and plaques. cIMT is validated by a substantial number of
prospective long-term outcome studies. These have been per-
formed in the general population, with sufﬁcient number of events
(myocardial infarction and stroke) and have included individuals at
risk from various ethnic groups. Carotid plaque has incremental
value to cIMT in risk assessment. Carotid ultrasound is relatively
easy to use and can be applied to daily practice given the wide-
spread availability of ultrasound devices [51].
The main disadvantage of cIMT is its low, yet signiﬁcant, inde-
pendent predictive power for future CV events over established risk
scores. Increased cIMT values may not be solely attributed to athe-
romatosis of the intima; hypertension results in thickening of the
media and, thus, in thicker cIMT. Nevertheless, the combined
assessment of cIMT and plaque presence improves risk prediction.
The meta-analyses suggest that cIMT measurements should not be
routinely performed in the general population. The initial cost of the
ultrasound device, probe and software, as well as training of
sonographers should also be considered. Methodological issues
pertaining to the site ofmeasurements impede comparisons of cIMT
values from different laboratories. Structured training and certiﬁ-
cation of sonographers should be sought, as well as certiﬁcation for
centres performing cIMT measurements by reference centres. The
calibration of different ultrasound devices on the basis of a common
phantomwould be an additional step towards standardization; this
approach has already been used for strain analysis in echocardiog-
raphy (“The Leuven approach”). The cost-effectiveness of cIMT
measurements and concomitant treatment should be assessed in
depth. Regarding plaques, these are mainly prevalent in the elderly,
which limits or even excludes their assessment in younger subjects
below the age of 40e50 years. Currently, the low availability of 3D
ultrasound, which can quantify total plaque volume and other
plaque characteristics hampers detailed plaque characterization.
Current status in clinical practice guidelines:
The European Society of Hypertension/European Society of
Cardiology (ESH/ESC) guidelines for the management of hyper-
tension have endorsed ultrasound scanning of the carotid arteries
for cIMT measurement and plaque detection [23]; this is also the
case in the ESC guidelines for CV disease prevention in individuals
at intermediate risk (class IIa/B recommendation in bothguidelines) [24]. The American College of Cardiology Foundation/
American Heart Association (ACCF/AHA) guidelines propose a IIa/B
recommendation for risk assessment in individuals with inter-
mediate risk (10-year risk for CV events of 6e20%) [52]. The most
recent ACC/AHA guidelines for the assessment of CV risk in
asymptomatic adults have given cIMT a class III/B recommenda-
tion for predicting a ﬁrst atherosclerotic CV disease event; plaque
assessment was not reviewed in these guidelines [3] (Table 6).
3. Ankle-brachial index (ABI)
Usefulness for primary and secondary CV disease prevention
(Recommendation/Level of evidence): IIa/A.
In healthy individuals, systolic BP levels are physiologically
higher in the lower extremities as compared to the arms; this is a
combined effect of pulse wave reﬂections and ampliﬁcation, as well
as changes in vessel wall thickness attributed to hydrostatic pres-
sure. This relationship can be quantiﬁed by the ratio of ankle-to-
brachial systolic pressure, termed ABI; a decrease of this ratio
heralds a late stage of atherosclerosis with hemodynamic
compromise attributed to obstructive lesions. First described as a
non-invasivemethod to diagnose lower extremity peripheral artery
disease (PAD) [53], ABI has been subsequently scrutinized as a
marker of CV disease prognosis, once the high risk of mortality and
morbidity of patients with PAD was evidenced [54].
Methodology:
Its mode of measurement and calculation has recently been
harmonized [55]. The standard mode of measurement requires a
(handheld) continuous wave Doppler device and a manual blood
pressure (BP) cuff. From this respect, it is one of the less expensive
and most available methods to detect atherosclerosis and stratify
CV risk. While ABI is traditionally calculated at each ankle by taking
the highest pressure between the systolic BPs of the posterior tibial
and dorsalis pedis artery divided by the highest systolic BP between
both arms, the lower of the 2 lower limbs ABI is retained to assess
CV risk of the subject [55]. In healthy subjects at low risk for PAD,
trivial intrinsic differences of ABI values have been reported be-
tween men and women, and in subjects of African descent versus
other ethnic groups [56]. While these small differences (<0.02) may
impact the estimation of PAD in these different groups, they are not
clinically relevant at an individual level, so similar normal values
are accepted.
The ABI threshold to diagnose PAD is commonly at 0.90. At
higher levels (>1.40) ABI identiﬁes medial calcinosis, i.e. calciﬁca-
tion of the tunica media without affecting the arterial lumen, a
condition distinct from atherosclerosis. Stiffened arteries due to
this disease are mostly observed in aged population, especially in
case of diabetes and/or end-stage renal failure.
Fulﬁlment of surrogate endpoint criteria:
1. Proof of concept: This is intuitive, as PAD (i.e. a low ABI) is
causally linked to CV risk factors (Table 2).
2. Prospective validation and 3. Incremental value: Several
longitudinal studies in the general population have demonstrated
the predictive ability of ABI for overall and CV mortality and
morbidity (Table 3). In an individual-basedmeta-analysis collecting
data of >48,000 men and women through 16 studies, it has been
demonstrated that an ABI <0.90 is associated with increased risk of
mortality (hazard ratio [HR]: 3.33 in men and 2.71 in women) [57].
Actually the risk of mortality (or CV events) increases when ABI
values fall below 1.10, but becomes more signiﬁcant and consistent
below 0.90. Subjects with an ABI between 1.10 and 1.40 are at the
lowest risk levels of CV events. In case of high (>1.40) ABI, the risk of
total and CV mortality is also increased [57]. However, in this case,
the intra-arterial pressure of leg arteries cannot be accurately
estimated by the cuff. In approximately half of these cases,
Table 4
Assessment of vascular biomarkers.
Proof of
concept
Prospective
validation
Incremental
value
Clinical utility Clinical
outcomes
Cost-
effectiveness
Ease of use Methodological
consensus
Reference values
Carotid ultrasonography þþþþ þþþ þþþ þþ þ/ þ þþ þþ Yes, for cIMT
measured with
the echotracking
method.
Ankle-brachial index þþþþ þþþþ þþþ þþþ þ/ e þþþþ þþþþ Diagnostic
thresholds
for PAD (cutoff
value: 0.90)
Arterial stiffness
Carotid-femoral pulse
wave velocity
þþþþ þþþþ þþþþ þþþ þ e þþþ þþþ Yes
Brachial-ankle pulse
wave velocity
þþþþ þþþ þþ þ e e þþþþ þþþ Yes, for Asian
populations.
Central haemodynamics/
Wave reﬂections
þþþþ þþþ þþþ þþ þ e þþþ þþþ Yes
Endothelial function
Flow mediated dilatation þþþþ þþþ þ þ þ/ e þ þþ No
Endothelial peripheral
arterial tonometry
þþþ þþ þ e e e þþþ þ No
Circulating biomarkers related to vascular wall biology
High sensitivity C-
reactive protein
þþþ þþþ þþ þþþ þþ þ þþþþ þþþ Cutoff value: 2 mg/L.
C. Vlachopoulos et al. / Atherosclerosis 241 (2015) 507e532 513occlusive artery disease due to atherosclerosis coexists [58]. Two
studies support the hypothesis that in patients with very high ABI,
only those with concomitant medial calcinosis and occlusive dis-
ease are at increased risk of death [59,60]. Hence, in case of an ABI
>1.40, further tests (e.g. toe-brachial index, or Doppler ﬂow anal-
ysis) is mandatory to reﬁne the risk estimation.
4. Clinical utility: Owing to its diagnostic role for PAD (values
<0.9 or >1.4), ABI can change predicted risk sufﬁciently to change
recommended therapy. The ARIC study reported modest risk pre-
diction improvement with use of ABI in addition to the FRS; this
needs further evaluation, especially because ABI was measured
only in one leg, so that it is estimated that 1/4th of PAD cases were
not detected [61]. In addition, the oscillometric methodwas used to
determine limb pressures [55,62]. The validity of this method to
estimate accurately ankle artery pressure is still a matter of con-
troversy, since it presents uncertain validity and reproducibility in
case of PAD [54,55].
The ABI collaboration meta-analysis showed that 19% of men
and 36% of women can have their risk estimation reclassiﬁed if the
ABI is performed in addition to the FRS [57]. In predicting events,Table 5
Usefulness of vascular biomarkers for primary and secondary CVD prevention.
Recommendation
Carotid ultrasonography IIa
Ankle-brachial index IIa
Arterial stiffness
Carotid-femoral pulse wave velocity IIa
Brachial-ankle pulse wave velocity IIb
Central haemodynamics/Wave reﬂections IIb
Endothelial function
Flow mediated dilatation III
Endothelial peripheral arterial tonometry III
Circulating biomarkers related to vascular wall biology
High sensitivity C- reactive protein IIbthe C-index increased modestly in men, from 0.672 when using the
FRS alone to 0.685 when adding ABI to FRS, and improved
dramatically in women, from 0.578 to 0.690, with NRI of 4.3% in
men and 9.6% in women. Restricting the analysis in those at in-
termediate 10-year risk of 10e19% resulted in higher NRIs, both in
men (15.9%) and women (23.3%) [63]. In an intermediate-risk
subgroup from the Framingham Offspring Study, an NRI of 7.9%
for coronary heart disease was reported [64] (Table 3).
5. Clinical outcomes:Whether the use of ABI can ultimately lead
to improved prognosis after prompt intervention requires further
investigation in randomized controlled trials. One open trial
comparing aspirin 100 mg vs. placebo in patients with ABI <0.90
detected after a large population screening failed to show any
beneﬁt after 8 years of follow-up [65]. In another double-blinded
trial limited to diabetic patients with ABI <1.0, aspirin 100 mg
was not superior to placebo to decrease mortality or CV events [66].
However, an analysis for the NHANES cohort [67] study suggests
better outcome in individuals with an ABI <0.90 who were at least
on two out of three major CV protective drugs (i.e. antiplatelet
agents, angiotensin-converting enzyme inhibitors [ACE-Is]/Level of evidence Comments
A Moderate usefulness for risk
stratiﬁcation. Concomitant
identiﬁcation of plaque presence.
A Useful for risk stratiﬁcation, especially women.
A Useful for risk stratiﬁcation.
B
B
B Requires skilled, trained operator.
Reactive hyperaemia is stressful.
Methodological problems are
not resolved. Added value is not proven.
C Reactive hyperaemia is stressful.
Added value is not proven.
B
Table 6
Implementation of vascular biomarkers in guidelines.
ESC/EASD guidelines on
diabetes, pre-diabetes
and cardiovascular
diseases (2013)
ESC/ESH guidelines
for the
management of
arterial
hypertension
(2013)
ESC guidelines on
cardiovascular disease
prevention in clinical
practice (2012)
ESC/EAS guidelines for the
management of
dyslipidaemias (2011)
ACC/AHA guideline
on the assessment
of cardiovascular
risk (2013)
ACC/AHA guideline
on the treatment of
blood cholesterol to
reduce
atherosclerotic
cardiovascular risk
in adults (2013)
ACCF/AHA guideline for assessment of
cardiovascular risk in asymptomatic
adults (2010)
Carotid ultrasonography May be considered as
useful cardiovascular
marker, adding
predictive value to the
usual risk estimate.
Class IIa/level of
evidence: B
- Asymptomatic adults at
moderate risk: Class IIa/
level of evidence: B
It is indicated to screen for
dyslipidaemias in the presence
of increased cIMT or carotid
plaques.
Class III/level of
evidence: B
e Class IIa/level of evidence: B
Ankle-brachial index May be considered as
useful cardiovascular
marker, adding
predictive value to the
usual risk estimate.
Class IIa/level of
evidence: B
PAD is a high risk condition, and
lipid-lowering therapy (mostly
statins) is recommended: Class
I/level of evidence: A
Class IIb/level of
evidence: B
e Class IIa/level of evidence: B
Arterial stiffness
Carotid-femoral pulse
wave velocity
May be considered as
useful cardiovascular
markers, adding
predictive value to the
usual risk estimate.
Class IIa/level of
evidence: B
e e e e Class III/level of evidence: C
Brachial-ankle pulse
wave velocity
May be considered as
useful cardiovascular
markers, adding
predictive value to the
usual risk estimate.
e e e e e Class III/level of evidence: C
Central haemodynamics/
Wave reﬂections
e e e e e e e
Endothelial function
Flow mediated dilation e e e e e e Class III/level of evidence: B
Endothelial peripheral
arterial tonometry
e e e e e e e
Circulating biomarkers related to vascular wall biology
High sensitivity
C- reactive protein
e e - As part of reﬁned risk
assessment in patients
with an unusual or
moderate CVD risk
proﬁle: Class IIb/level
of evidence: B
- Asymptomatic low-risk
individuals and high-
risk patients: Class III/
level of evidence: B
- Individuals with increased
hsCRP have a higher risk
level than that calculated
from the SCORE chart
- Not recommended as a
secondary target of therapy
for everybody; however, it
may be useful in people close
to the high risk category to
better stratify their total CV
risk.
Class IIb/level of
evidence: B
High sensitivity-
CRP level >2mg/L is
an additional factor
to be considered
during treatment
decision making for
individuals without
atherosclerotic
disease
- Men 50 years old or women 60
years old with low-density lipopro-
tein cholesterol less than 130 mg/dL;
not on lipid-lowering, hormone
replacement, or immunosuppressant
therapy; without clinical CHD, dia-
betes, chronic kidney disease, severe
inﬂammatory conditions, or contra-
indications to statins: Class IIa/level
of evidence: B
- Asymptomatic intermediate-riskmen
50 years old or women 60 years
old: Class IIb/level of evidence: B
- Asymptomatic high-risk adults: Class
III/level of evidence: B
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C. Vlachopoulos et al. / Atherosclerosis 241 (2015) 507e532 515angiotensin receptor blockers and/or statins), but this merits
conﬁrmation with an appropriately designed trial. A meta-analysis
(n ¼ 11,686) reported that various drug classes improve walking
distance in patients with an ABI<0.90, albeit with limited beneﬁts;
statins were the most efﬁcient among them [68].
Apart from single measurements, ABI change over time can also
provide predictive information (except when revascularization is
performed, which usually leads to an ABI increase when success-
ful). An ABI decrease of more than 0.15 within 3 years was associ-
ated with a 2.4-fold risk increase of death, and 2.8-fold risk increase
of CVmortality [69]. With respect to its ability tomonitor and guide
therapy, intra- and inter-observer reproducibility is acceptable (at
best ±0.10) but not sufﬁcient to detect individual small values
change during follow-up [55]. At population level, ABI changes
slowly over time, so that this marker is not highly sensitive to risk
factor modiﬁcation or pharmacological intervention.
6. Cost-effectiveness: At present, no data regarding cost-
effectiveness have been published. Nonetheless, the initial cost of
the equipment is relatively low.
7. Ease of use: ABI can be easily measured after an initial training
regarding the use of the Doppler device.
8. Methodological consensus: The measurement and interpre-
tation of the ABI has been standardized [55].
9. Reference values: Cutoff points for PAD have been ascer-
tained, as mentioned above. The same cutoff points (values <0.90
or >1.40) are used to detect individuals at increased risk for CV
events independently of the presence of symptoms of PAD and
other risk factors [55,57].
In summary, ABI meets most of the 9 essential criteria to classify
as a clinical surrogate endpoint (Tables 4 and 5).
Advantages/disadvantages, issues remaining to be addressed
and future perspectives:
A unique advantage is that ABI is the only biomarker that has
both a diagnostic (for PAD) and prognostic (for CV disease and
mortality) role. An additional advantage is its wide availability, so
that it can currently be considered as the ﬁrst-line vascular
biomarker to be used in the setting of primary care; however,
skilled operators are required for consistent, accurate results. The
low cost of the equipment and the extensive validation are also
ranked among the strengths of the method.
The disadvantages of the ABI include false negative results in
patients with medial calcinosis because stiff arteries produce
falsely elevated ankle pressure (see above). Resting ABI is insensi-
tive to mild PAD; treadmill tests are sometimes used to increase
sensitivity, but this increases assessment duration and is unsuitable
for patients who are obese or have co-morbidities. Measurement of
the ABI can be time-consuming in the setting of PAD.
A number of issues are open. Devices using non-Doppler based
methodology should be accredited. Further research should explore
potentially easier and faster alternative methods for ABI measure-
ment that would likely be implemented more broadly in primary
care. Finally, the optimal method of ABI calculation for predicting
CV events and PAD merits additional investigation [55].
Current status in clinical practice guidelines:
TheESH/ESCguidelines for themanagementof hypertension state
that ABI should be considered for detecting PAD in hypertensives
(class IIa/B recommendation) [23]; the same holds true in the ESC
guidelines for CV disease prevention in individuals at intermediate
risk (class IIa/B recommendation) [24]. The European Society of Car-
diology/European Association for the Study of Diabetes (ESC/EASD)
guidelines for diabetes and pre-diabetes state that ABI may be
considered as a useful marker that adds predictive value to the usual
risk estimate [70]. The U.S. Preventive Services Task Force concluded
that the current evidence is insufﬁcient to assess the balance of
beneﬁts and harms of screening for PAD and CVD risk assessmentwith the ABI [71]. According to the ACCF/AHA guidelines, measure-
ment of ABI is reasonable for the assessment of CV risk in asymp-
tomatic adults (class IIa/B recommendation) [52]. The most recent
ACC/AHA guidelines state that ABI measurement may be considered
if, after quantitative risk assessment, a risk-based treatment decision
is uncertain (class IIb/B recommendation) [3] (Table 6).
4. Arterial stiffness
Arterial stiffening results primarily from arteriosclerosis (prin-
cipally a disease of the media, related to normal or accelerated
aging) rather than from atherosclerosis (principally a disease of the
intima, affecting the vessel in a patchy and not uniform manner).
Because waves travel faster in a rigid tube, loss of compliance re-
sults in increased velocity of pulse waves; therefore, a high pulse
wave velocity is a hallmark of arteriosclerosis. CV risk factors alter
the composition andmechanical properties of arterial walls making
them eventually less compliant. Elastic-type arteries, such as the
aorta, are primarily affected, as opposed to muscular arteries.
A multitude of invasive and non-invasive methods measuring
arterial stiffness have been described. The most widely used and
validated techniques involve the assessment of pulse waves as they
travel over a signiﬁcant portion of the arterial tree; regional (over
shorter arterial segments) and local (carotid or femoral) arterial
stiffness are emerging as promising biomarkers [72]. Carotid-
femoral pulse wave velocity (cfPWV) and brachial-ankle PWV
(baPWV) are dealt with herein. Cardio-ankle vascular index (CAVI)
has been recently introduced. CAVI is primarily used in Japan and
has the theoretical advantage to be less dependent on BP levels.
CAVI had been correlated with several arteriosclerotic and
atherosclerotic diseases [73].
4.1. Carotid-femoral pulse wave velocity (cfPWV)
Usefulness for primary and secondary CV disease prevention
(Recommendation/Level of evidence): IIa/A.
cfPWV, i.e. the velocity of the pulse as it travels from the heart to
the carotid and the femoral artery, remains the most commonly
used non-invasive method and is considered as the “gold standard”
[74]. Data regarding risk prediction are less consistent concerning
local stiffness, i.e. carotid stiffness measured with high-resolution
echotracking systems, or arterial stiffness measured at other arte-
rial sites such as carotid-radial PWV and femoro-tibial PWV.
Methodology:
cfPWV is usually measured using the “foot-to-foot” velocity
method from a number of waveforms. These are usually obtained
using surface tonometry probes at the right common carotid artery
and the right femoral artery and the time delay (Dt, or transit time)
is measured between the “foot” of the two waveforms [75]. The
“foot” of the wave is deﬁned at the end of diastole, when the steep
rise of the wavefront begins. The transit time is the time of travel of
the “foot” of the wave over a known distance. A variety of different
waveforms can be used including pressure [75], distension [76] and
ﬂow [77]. The distance D covered by the waves is usually assimi-
lated to the skin distance between the two recording sites, i.e. the
common carotid artery and the common femoral artery. PWV is
calculated as PWV ¼ D/Dt (m/s).
Fulﬁlment of surrogate endpoint criteria:
1. Proof of concept: A large number of studies have reported the
various physiological and pathophysiological conditions associated
with increased arterial stiffness [74]. Apart from the dominant ef-
fect of BP and aging, these include genetic background, CV risk
factors and diseases, and also primarily non-CV diseases (such as
end-stage renal disease [78]) and chronic inﬂammatory diseases
(such as inﬂammatory bowel disease [79]). Arterial stiffness is a
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(Table 2).
2. Prospective validation and 3. Incremental value: The pre-
dictive value of arterial stiffness has been largely demonstrated.
Currently, numerous studies in patients with uncomplicated
essential hypertension [80e82], type 2 diabetes mellitus [77], end-
stage renal disease [83], elderly subjects [84,85] and the general
population have prospectively validated cfPWV [86]. The inde-
pendent predictive value of arterial stiffness has also been
demonstrated for neurologic functional outcome after stroke [87].
Arterial stiffness is a robust predictor of all-cause and CV mortality,
fatal and non-fatal coronary events and fatal strokes [88,89], thus it
can be considered as an intermediate endpoint for CV events [90].
In an individual data meta-analysis, CV disease events increased by
30% per 1-standard deviation (SD) increase of cfPWV (95% CI:
1.18e1.43) after adjustment for traditional risk factors [88]. The
independent association with all-cause mortality merits attention,
as it indicates that the role of arterial stiffness extends beyond
diseases of the CV system. Moreover, it should be noted that the
independent predictive value of arterial stiffness has been
demonstrated after adjustment for classical CV risk factors,
including brachial pulse pressure. In addition, arterial stiffness re-
tains its predictive value for CV events after adjustment for the FRS
[80] or SCORE [91], suggesting that it has an added value to a
combination of CV risk factors (Table 3).
4. Clinical utility: Two studies and an individual data meta-
analysis showed that patients at intermediate risk could be
reclassiﬁed into a higher or lower CV risk category when arterial
stiffness was measured [86,91,92]. Speciﬁcally, in the Framingham
study 15.7% of patients at intermediate risk could be reclassiﬁed
into a higher (14.3%) or lower (1.4%) risk category [92]. In a recently
published individual data meta-analysis (n ¼ 17,635 participants),
the 5-year overall NRI for coronary heart disease and stroke in in-
termediate risk individuals was 14.8% and 19.2% respectively [88].
Finally, 29% of patients with chronic kidney disease were reclassi-
ﬁed into lower or higher risk for all-cause mortality when arterial
stiffness was taken in to account [93] (Table 3).
5. Clinical outcomes: No study or randomized controlled trial
has yet assessed the potential of cfPWV as a target for therapy and
whether such a strategy would result in better clinical outcomes.
One study in end-stage renal disease patients showed a better
outcome for those that decreased their arterial stiffness [94]; this
remains to be validated in a larger population of patients at lower
CV risk. Such a study is currently underway [90].
6. Cost-effectiveness: No data are currently available. Wide
adoption of the technique leads to continuous reduction of device
cost; the potential for cost saving is high given the low cost of in-
dividual examination and high reclassiﬁcation.
7. Ease of use: Accurate recording of carotid and femoral pulses
is easily performed after a short learning period; exposure of the
inguinal region is, however, a drawback.
8. Methodological consensus: An expert consensus document
for the measurement of cfPWV in daily practice has been published
[76].
9. Reference values: Reference values for PWV have been
established in 1455 healthy subjects and a larger population of
11,092 subjects with CV risk factors [95]. These are reported ac-
cording to age and BP levels. Although the relationship between
cfPWV and CV events is continuous, a threshold of 12 m/s had been
initially suggested as a conservative estimate of signiﬁcant alter-
ations of aortic function in middle aged hypertensives [74], and
included in the ESH/ESC guidelines for the management of hyper-
tension. This threshold was based on cfPWV using the full direct
carotid-to-femoral distance and has been revised in a recent
consensus document to 10 m/s [76], in order to normalise PWVvalues according to the arterial pathway. Accordingly, the investi-
gator should preferentially use the direct carotid-femoral distance
and multiply by 0.8 only marginally overestimating the real trav-
elled distance by 0.4% [76,96]. The new threshold is included in the
2013 ESH/ESC guidelines for the management of hypertension [23].
In sum, cfPWV meets most of the 9 essential criteria to classify
as a clinical surrogate endpoint (Tables 4 and 5).
Advantages/disadvantages, issues remaining to be addressed
and future perspectives:
Aortic stiffness, as measured by cfPWV, integrates the damage of
risk factors on the aortic wall over a long period, whereas BP, gly-
caemia, and lipids can ﬂuctuate and their values, recorded at the
time of risk assessment, may not reﬂect the average values
damaging the arterial wall. Nevertheless, cfPWV is strongly inﬂu-
enced by age and BP levels, while the inﬂuence of other risk factors
is weaker [97]. Its non-invasive nature, fast learning curve, thewide
choice of available devices/no absolute need for a proprietary de-
vice, relatively low cost, extensive validation in large population
studies and established reference values are among its advantages.
On the other hand, exposure of the inguinal region for measure-
ments and a calibration of the measured travelled distance are
needed.
cfPWV meets most of the criteria to qualify as a surrogate
endpoint for CV disease. Currently, studies that address its ability to
monitor and guide therapy and eventually improve outcomes are in
progress; though it cannot be considered yet as a surrogate
endpoint, it is at an advanced stage of validation.
Current status in clinical practice guidelines:
At present, the ESC guidelines for individuals at intermediate
risk acknowledge the added value of cfPWV for the stratiﬁcation of
patients [24]. Moreover, it should be considered for hypertensives
(class IIa/B recommendation) [23], and it can add predictive value
to the usual risk estimate of diabetics [70]. In contrast, it is not
recommended by the ACCF/AHA guidelines for the assessment of
CV risk in asymptomatic adults (class III/B recommendation) [52];
nevertheless, these need to be reappraised in the light of recent
data [88]. (Table 6)
4.2. Brachial-ankle pulse wave velocity (baPWV)
Usefulness for primary and secondary CV disease prevention
(Recommendation/Level of evidence): IIb/B.
baPWV is a method for assessing arterial stiffness. Though it
shares the same theoretical background with cfPWV, baPWV cap-
italizes on the concept that measurements over a longer arterial
length may provide additional information and be easier, as it only
involves wrapping of a pressure cuff in each of the four exposed
extremities [98]. The method has is being primarily used in Japan.
Methodology:
baPWV is measured using a volume-plethysmographic appa-
ratus. Occlusion cuffs, connected to both plethysmographic and
oscillometric sensors, are wrapped around both upper arms and
ankles of the subjects lying in the supine position. The brachial and
posterior tibial arterial pressure waveforms are recorded by the
plethysmographic sensor. The path lengths from the suprasternal
notch to the brachium (Lb) and from the suprasternal notch to the
ankle (La) are obtained from superﬁcial measurements and cor-
rected for the height of the individual using validated equations.
baPWV is then calculated according to the equation: baPWV ¼
(LaLb)/DTba, where DTba is the time interval between the
wavefront of the brachial waveform and that of the ankle
waveform [99].
Considering the results of published prospective studies, a
baPWV value of 18 m/s may be used as a cutoff value in the
assessment of the risk for CV disease [100,101]. Due to the fact that
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describing the correlation of the three variables is available [102].
Fulﬁlment of surrogate endpoint criteria:
1. Proof of concept: baPWV has been well validated as a CV risk
marker, as it is closely correlated not only with cfPWV, but alsowith
aortic PWV assessed by the invasive method [98,103]. Similarly to
cfPWV, the presence of CV risk factors is linked to elevated baPWV
values [104] (Table 2).
2. Prospective validation and 3. Incremental value: For primary
prevention, several prospective studies have reported that baPWV
may be a useful predictor of future CV events in patients with end-
stage renal disease, hypertension and in the general population
[100,105]. For secondary prevention, baPWV has been suggested as
a useful predictor of the prognosis in patients with acute coronary
syndromes and heart failure [101,106]. Some prospective studies
also demonstrated that an elevated baPWV is a predictor of pro-
gression of pathophysiological abnormalities in the early stages of
hypertension and chronic kidney disease [103]. A meta-analysis
demonstrated that an increase in baPWV by 1 m/s was associated
with an increase by 12%, 13% and 6% in CV events, CV mortality, and
all-cause mortality, respectively; the independent predictive value
of baPWV was established when studies that had controlled for
most CV risk factors were subsequently analyzed [107]. The po-
tential clinical advantage of baPWV over traditional risk scores has
not been, however, formally proven (Table 3).
4. Clinical utility: No data exist regarding the potential of the
method for reclassiﬁcation and subsequent implications for ther-
apy. Despite that, an improvement in baPWV following drug ther-
apy for hypertension, dyslipidaemia and diabetes mellitus and
lifestyle modiﬁcations (exercise, weight reduction, smoking
cessation) has been shown [108].
5. Clinical outcomes: No studies exist to date to substantiate the
prospect that treatment according to baPWV values can lead to
better clinical outcomes.
6. Cost-effectiveness: The cost-effectiveness of this method has
not been addressed yet.
7. Ease of use: The technique is easy to use, as measurements are
automatically performed after cuff placement at the extremities.
8. Methodological consensus: Measurements are performed
according to manufacturer's instructions; however, a consensus
paper has not been published.
9. Reference values: Reference values have been published for
Chinese populations [109,110]; no data exist for non-Asian pop-
ulations. Similar to cfPWV, these are reported according to age and
BP levels.
In conclusion, baPWV meets some of the 9 essential criteria in
order to be considered a clinical surrogate endpoint (Tables 4 and
5).
Advantages/disadvantages, issues remaining to be addressed
and future perspectives:
Simplicity and concurrent ABI measurement (albeit with the
oscillometric method; see section 3. ABI) with the same device are
considerable advantages. The disadvantages of the method include
issues pertaining to calculation of travelled distance (height-based
formulas), need for validation in diverse populations and lack of
reference values. Importantly, applicability may be limited when
arteries of smaller calibre are affected, such as in diabetes mellitus
or in distal PAD.
It should be emphasized that cfPWV data (which assess pre-
dominantly elastic type arteries) are not automatically extrapolated
to baPWV, which reﬂects the stiffness of the large-to middle-sized
arteries, and therefore, elastic arteries are assessed along with
muscular and mixed-type arteries [98].
Comparisons with the “gold standard” method of cfPWV are
needed. Despite the fact that the incremental value of baPWV overand above traditional risk factors has been demonstrated in high-
risk populations, prospective studies are needed to examine its
incremental value over risk scores in the general population.
Moreover, it is currently unknown whether improvement of
baPWV with interventions might also translate into successful
prevention of CV events.
Current status in clinical practice guidelines:
At present, baPWV has not been endorsed by guidelines
(Table 6).
5. Central haemodynamics/wave reﬂections
Usefulness for primary and secondary CV disease prevention
(Recommendation/Level of evidence): IIb/B.
Left ventricular afterload is dependent on aortic valve and pe-
ripheral circulation properties (steady-state component) and on
the elasticity of the aorta and the large arteries (pulsatile compo-
nent). Different models allow quantiﬁcation of systemic circulation
mechanics. In the most realistic ones, pressure and ﬂow waves are
generated with each heartbeat and are propagated towards the
periphery where they are reﬂected backwards (towards the heart)
for various reasons (stiffness gradient, presence of bifurcations,
abrupt diameter gradient in arterioles). On their return, the re-
ﬂected waves merge with the antegrade wave and amplify it [111].
As a result of this (but not exclusively), peripheral BPs are higher
compared to central (aortic) BPs to a varying degree, a phenomenon
named “ampliﬁcation” [112]. Central BPs are more relevant than
peripheral ones, as the heart, brain and kidneys are directly
exposed to them [113]. With aging, the arrival of reﬂected waves in
the ascending aorta is shifted into systole due to earlier wave re-
turn; this is largely attributed to increased aortic stiffness/PWV and
the resulting wave changes shape. With vasoconstriction, the
amplitude of the reﬂected pressure waves increases. Both these
processes lead to increased central systolic pressure (increased
cardiac load and oxygen consumption), lower diastolic pressure
(decreased myocardial perfusion pressure) and promotion of
degeneration of the elastic components of the arterial wall. The net
result is an imbalance towards myocardial ischaemia and an
impairment of (mainly diastolic) left ventricular function. Of note,
in the presence of systolic heart failure the forward wave is of lesser
magnitude and as a result, wave reﬂections are reduced.
Methodology:
Central haemodynamic indices are either central BP parameters
and derivatives (central systolic BP, pulse pressure, augmented
pressure and ampliﬁcation) or indices that quantify wave re-
ﬂections [augmentation index (AIx), forward and backward wave,
wave intensity analysis]. Invasive recordings provide accurate
measurements of central pressures and wave reﬂection. In clinical
studies, however, non-invasivemethods are used for quantiﬁcation.
Classical pulse wave analysis [111] involves analysis of pressure
waves alone, from the carotid, radial, or brachial artery. The sub-
sequent use of a transfer function (or special algorithms) and
calibration to non-invasively measured pressure yields parameters
of the central waveforms, such as central (aortic) pressure,
augmentation pressure (measure of the enhancement of central
aortic pressure by the reﬂected pulse wave) and AIx (augmentation
pressure to pulse pressure ratio). From pressure waves and simul-
taneously acquired or estimated ﬂow waves [114], wave separation
analysis (assumes a set forward wave, a limitation of the approach)
has been used to acquire amplitudes of forward (Pf) and backward
(Pb) waves and their ratio, termed reﬂection magnitude. It should
be emphasized that indices and their individual validation for
clinical use are not interchangeable; for example, augmented
pressure and reﬂection magnitude have a better predictive ability
than the AIx [115,116].
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1. Proof of concept: Increased wave reﬂection is related to the
extent of myocardial ischaemia in patients with [117] and without
[118] obstructive coronary artery disease. Moreover, it is directly
related to left ventricular hypertrophy [119] and its regression with
treatment [120], to left atrial size [121], and is inversely related to
left ventricular diastolic function at rest [121] and during exercise
[122]. Measures of wave reﬂection can improve the diagnostic ac-
curacy in patients with suspected heart failure with preserved
ejection fraction [121]. An increase in wave reﬂection has been
associated with a decreased renal function [123] and with an
impaired outcome following acute ischemic stroke [87] (Table 2).
2. Prospective validation and 3. Incremental value:Measures of
wave reﬂection have consistently been reported to be independent
predictors of either CV events or CV mortality in high risk pop-
ulations: patients with impaired renal function [124], renal trans-
plant recipients [115], dialysis patients [78], patients undergoing
coronary interventions [125], patients undergoing coronary angi-
ography [126], and patients hospitalized due to acute heart failure
[127]. Results are less consistent in broader populations: in most
[116,128], but not all [92] community-based studies an indepen-
dent predictive value of measures of wave reﬂections has been
shown. Results are heterogeneous in studies on hypertensive pa-
tients [129] and in geriatric patients [130]. In almost all studies, the
predictive value was additional to that of brachial BP.
In a meta-analysis of 5648 subjects, central systolic BP, central
pulse pressure and central AIx were independent predictors of CV
events; of interest, central AIx also independently predicted all-
cause mortality, a ﬁnding that extends its role beyond the CV sys-
tem. Central pulse pressure had a marginally signiﬁcant (P¼ 0.057)
better predictive ability for clinical events when compared with
peripheral pulse pressure [131]; when one study with methodo-
logical shortcomings was excluded, statistical signiﬁcance was
reached [132,133] (Table 3).
4. Clinical utility: In the largest population study, wave re-
ﬂections (expressed as reﬂection magnitude) predicted the occur-
rence of heart failure and severe CV events [116]. Several novel
indices of clinical utility and reclassiﬁcation were computed,
showing an NRI of 13% for hard CV events and of 38% for heart
failure, as compared to models that included brachial systolic and
diastolic BP among other traditional risk factors (Table 3).
5. Clinical outcomes: Antihypertensive drug trials have
demonstrated an improvement in intermediate endpoints, such as
left ventricular mass, following a reduction of wave reﬂections and
central pressures [134,135]. Evidence showing that an improve-
ment in wave reﬂection will lead to a reduction in CV events was
provided by the Conduit Artery Functional Evaluation (CAFE) study,
where, despite a similar reduction in peripheral systolic BP, a
calcium-channel blocker regimen was more effective in lowering
central systolic BP, and reduced future CV events compared to a
beta-blocker regimen [129].
6. Cost-effectiveness: No studies so far have investigated the
cost effectiveness of measures of central haemodynamics/wave
reﬂections. Nevertheless, the use of central BPs, compared to pe-
ripheral BPs, for guiding antihypertensive treatment led to less use
of medications [136]. The assessment of central haemodynamics is
valuable in the evaluation of young persons with isolated systolic
hypertension by identifying those who do not have concurrently
increased central pressures, a common pattern, thus obviating the
need for further investigations and drug treatment [23,137].
7. Ease of use: Assessment of wave reﬂections/central BPs with
peripheral tonometry can be made by validated, non-invasive de-
vices. Cuff-based techniques are more easy to use and offer
simultaneous assessment of both brachial and aortic BP, as well as
the opportunity of 24-h recordings; they predict left ventricularhypertrophy more accurately than peripheral ambulatory blood
pressure monitoring [138]. Nevertheless, the technical validation of
these latter devices is ongoing and needs to be done at rest and
with exercise [139,140].
8. Methodological consensus: It is yet unclear which index will
prove to be themost useful for clinical practice and how this should
be measured. A consensus statement on central BP measurements
and antihypertensive therapy has been published; an updated
version is warranted [141].
9. Reference values: Reference values for central haemody-
namics have been recently published [142].
As a result, wave reﬂections and central haemodynamics meet
some of the 9 essential criteria to classify as a clinical surrogate
endpoint (Tables 4 and 5)
Advantages/disadvantages, issues remaining to be addressed
and future perspectives:
Advantages include the strong physiological background and
the clinical value in high-risk patients. The incremental value of
wave reﬂections/central haemodynamics has been shown to some
degree; however, more data are needed regarding clinical utility,
improvement of clinical outcomes and cost-effectiveness.
Because peripheral pressure is necessary to calibrate central
pressure, their respective clinical values cannot be easily disen-
tangled. It needs to be clariﬁed, which is the ideal measure of wave
reﬂections (pulse wave analysis-based indices: AIx, augmented
pressure; wave separation analysis-based indices: amplitude of
backward wave, reﬂection magnitude; wave intensity analysis-
based indices: wave reﬂection index, intensity of forward
compression and expansion waves) and central pressures. Simpli-
ﬁcations of systems for assessment that facilitate adoption by cli-
nicians are welcome.
Current status in clinical practice guidelines:
The ESH/ESC guidelines for the management of arterial hyper-
tension state that central BPs/AIx can be helpful when assessing
young patients with isolated systolic hypertension; however, more
data are required before central haemodynamic indices are rec-
ommended for routine use in hypertensives in general [23]
(Table 6).
6. Endothelial function
Amultitude of techniques for assessing endothelial function have
been described. The focus of this document is on non-invasive
methods owing to their ease of use that permits implementation
in clinical practice beyond vascular laboratories. Invasive methods
and laboratory techniques requiring high levels of technical exper-
tise remain outside the scope of this document and will not be
addressed. Such methods (coronary endothelial function, venous
occlusion plethysmography, pulse wave analysis for endothelial
function assessment, laser Doppler ﬂowmetry, biochemical markers
and bioassays, endothelial microparticles, progenitor cells and gly-
cocalyx) have been previously reviewed in a position statement by
the ESC Working Group on Peripheral Circulation [143].
6.1. Flow-mediated dilation (FMD)
Usefulness for primary and secondary CV disease prevention
(Recommendation/Level of evidence): III/B.
The endothelium regulates all aspects of vascular homeostasis
by releasing vasoactive molecules in response to physical and
chemical stimuli. Endothelium-derived nitric oxide (NO) is the
main mediator of all vasoprotective effects; NO is a very potent
vasodilator but also has anti-inﬂammatory, anti-proliferative and
antithrombotic properties. Reduced NO bioavailability, due to
reduced production and/or increased inactivation, results from
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present very early in the atherosclerotic process, long before
structural changes in vessel wall are evident [144]. This dysfunction
contributes to the development and progression of atherosclerosis
and even plaque rupture [143].
Endothelial function was initially assessed using invasive
methods and pharmacological stimuli in the coronary arteries and
in the peripheral resistance arteries (venous occlusion plethys-
mography). Brachial artery FMD was the ﬁrst non-invasive tech-
nique to assess endothelial function in the peripheral conduit
arteries [145] and remains today the most widely applied method
[143].
Methodology:
FMD is an endothelium-dependent, NO-mediated process that
uses high-resolution ultrasound in the brachial artery bymeans of a
high frequency linear transducer to monitor changes in arterial
diameter in response to increased blood ﬂow, an important phys-
iological stimulus for endothelial NO production [146]. In brief,
images are acquired at baseline and after deﬂation of a cuff inﬂated
to at least 50 mmHg above systolic BP [146] or at about 250 mmHg
[147] for a set length of time, usually 4e5min. Placement of the cuff
above or below the elbow has been the subject of controversy;
upper versus lower cuff placement maximizes hyperaemic
response but distorts the brachial artery and introduces variability
in results. FMD is deﬁned as the maximum percent increase in
arterial end-diastolic diameter during the ﬁrst minutes of hyper-
aemia compared with the diameter at rest [147]. To assess the
endothelium-independent smooth muscle capacity to dilate,
nitrate-mediated dilation is also determined as the percent in-
crease in brachial artery diameter 4 min after administering sub-
lingual glyceryl trinitrate. FMD has been closely correlated with
endothelial function assessed in the coronary circulation [145,148];
variability across laboratories and reproducibility over the short
and medium term are vey good [149].
Fulﬁlment of surrogate endpoint criteria:
1. Proof of concept: Endothelial dysfunction, assessed by
impaired FMD, has been extensively associated with most of the
established and emerging CV risk factors (e.g. dyslipidaemia, hy-
pertension, smoking, diabetes mellitus, family history of premature
atherosclerosis, elevated plasma homocysteine), as well as with the
presence and extent of structural arterial disease and prevalent CV
disease. Assessment of endothelial dysfunction using FMD appears
to complement other imaging endpoints of structural arterial dis-
ease burden, probably preceding their occurrence [150] (Table 2).
2. Prospective validation and 3. Incremental value: FMD has
been prospectively validated in predicting future CV events. Its
prognostic value has been demonstrated in patients with advanced
atherosclerosis, in subjects at high CV risk andmore recently also in
low-risk subjects, although this was not a consistent ﬁnding in all
studies. Three meta-analyses showed an independent prognostic
value [151e153]; for each 1% increase in FMD, risk was decreased by
13% (relative risk [RR]: 0.87; 95% CI: 0.83e0.91), 8% (RR: 0.92; 95%
CI: 0.88e0.95) and 10% (RR: 0.90; 95% CI: 0.88e0.92) respectively.
The correlation of FMD with risk was stronger in populations with
overt CV disease.
The incremental value of FMD in addition to classical CV risk
factor evaluation using risk scores such as the SCORE and FRS has
not been established. Few studies so far have reported on the in-
cremental value of FMD using the change in the area under the
curve with conﬂicting results [154]. (Table 3) Of note, invasive
methods for assessment of endothelial function have shown in-
cremental value over the FRS [155].
4. Clinical utility: The reclassiﬁcation potential of FMD has been
examined in the MESA cohort; in intermediate risk individuals the
NRI was 2.4% for incident coronary heart disease [64]. (Table 3)5. Clinical outcomes: Numerous studies have incorporated FMD
measurements because it improves rapidly with physiological and
pharmacological interventions (e.g. statins, ACE-Is, calcium channel
blockers, exercise, weight loss, estrogen, antioxidants, vitamins,
dietary constituents). This reinforces the concept that endothelial
dysfunction, the earliest stage of atherosclerosis, is a reversible
process [156,157]. Nevertheless, whether an improvement in FMD
with treatment may also translate into improved clinical outcomes
has not been tested in a randomized controlled trial. In non-
randomized controlled studies, FMD improvement was associated
with a reduction in events in hypertensive postmenopausal women
[158], whereas persistent FMD impairment despite optimized
therapy was associated with an increase in CV events [159,160].
6. Cost-effectiveness: The cost-effectiveness of FMD has not
been studied so far.
7. Ease of use: FMD measurements require signiﬁcant technical
expertise; guidelines propose a minimum number of 100 super-
vised scans prior to scanning independently and at least 100 scans/
year to maintain competency [146].
8. Methodological consensus: Published guidelines have facili-
tated uniform FMD measurements [146]. Nevertheless, methodo-
logical differences have been reported regarding the level of
inﬂation pressure to cause ischaemia, duration of ischaemia,
brachial versus wrist cuff inﬂation and the time point at which the
effect of reactive hyperaemia is assessed.
9. Reference values: Currently there are no reference values for
FMD.
In conclusion, FMD does not fulﬁll the 9 essential criteria in
order to be considered a clinical surrogate endpoint (Tables 4 and
5).
Advantages/disadvantages, issues remaining to be addressed
and future perspectives:
FMD is an integrative marker of the damage from risk factors on
the arterial wall and a valuable research tool in the study of the role
of risk factors in atherosclerosis [146]. The most important role of
FMD appears to be its ability to monitor the effect of a treatment or
an intervention on endothelial function. Its rapid response to
treatment stirred the anticipation that it may replace studies of
traditional CV outcomes that take longer time and are more
expensive. The method is completely non-invasive and safe, easy to
use, reliable and repeatable in expert laboratories. FMD is limited
mainly by technical difﬁculties and methodological shortcomings.
Extensive training of the operator is needed resulting in a long
learning curve, and image analysis may be labor-intensive. Poten-
tial environmental/physiological inﬂuences (e.g. food, caffeine,
temperature, stress) need to be controlled for. Methodological
standardization is needed (cuff positioning, timing of response,
edge detection, software analysis, stereotactic probe-holding de-
vices) to reduce operator-dependence, improve reproducibility and
allow comparison among laboratories [161]. Normal and reference
values are yet to be established.
Evolution of themethodology is sought to establish applicability
in daily practice and acceptable cost/beneﬁt ratio. Furthermore, the
reclassiﬁcation of subjects at intermediate risk is still open to
question. Therefore, currently FMD remains mainly a valuable
research tool.
Current status in clinical practice guidelines:
The ESC guidelines have not endorsed FMD for clinical use either
for reﬁnement of risk stratiﬁcation [24] or for monitoring the effect
of treatment [23]. FMD has a class III/B indication in the ACCF/AHA
guidelines for the assessment of CV risk in asymptomatic adults
[52]. (Table 6)
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Usefulness for primary and secondary CV disease prevention
(Recommendation/Level of evidence): III/C.
Noninvasive, ﬁnger probe-based methods exist for endothelial
function assessment: digital thermal monitoring (DTM), digital
volume photoplethysmography (DVP) and, the most widely used,
endothelial peripheral arterial tonometry (EndoPAT). DTM (Endo-
thelix Inc., Houston, TX, U.S.A.) is a technique that shares the same
pathophysiological background with FMD using temperature as a
surrogate marker of blood ﬂow; nevertheless few studies with
small sample sizes have been published to date [162,163], Similarly,
DVP has been used for endothelial function assessment on top of its
use for pulse wave analysis [164], but there are limited published
data to date [165].
The pathophysiological background of EndoPAT is similar to that
of brachial FMD, since both assess endothelial function. Neverthe-
less, several studies have reported low to moderate correlation
between the two methods, suggesting that FMD and EndoPAT
provide distinct information regarding vascular function
[166e168]. These ﬁndings may be explained by the corrections
implemented in the EndoPAT (see Methodology section below),
whilst no such correction is incorporated in the brachial FMD
method, and by the difference in type of vessels measured e small
arteries and microcirculation in the case of EndoPAT versus single
conduit vessel in the case of brachial FMD [166,167,169].
Methodology:
EndoPAT is based on the noninvasive measurement of pulsatile
volume changes at the ﬁngertip by peripheral arterial tonometry
using a patented device (Itamar Medical, Caesarea, Israel). Essen-
tially, the method is a modiﬁcation of volume plethysmography.
Tests can be carried out with the patient positioned either sitting or
supine, with the sensors placed on the index ﬁnger of each arm. The
endothelium-mediated changes in the ﬁnger vasculature elicited
by a 5-min occlusion of the brachial artery are quantiﬁed, using a
standard BP cuff inﬂated to a suprasystolic pressure. When the cuff
is abruptly released, the surge of blood ﬂow causes an
endothelium-dependent FMD. The dilation is captured by the de-
vice as an increase in amplitude of the peripheral arterial tonom-
etry signal. A post-occlusion to pre-occlusion ratio is calculated.
Because the signal is also affected by additional, non-endothelial
dependent factors, those are corrected by measurements in the
contralateral arm. An additional correction is performed for base-
line values. Thus, the corrected values characterize the bio-
availablity of NO and therefore represent endothelial function. A
score is provided in either linear or logarithmic scale.
Fulﬁlment of surrogate endpoint criteria:
1. Proof of concept: EndoPAT has been incorporated in
numerous population-based studies such as the Framingham, the
Gutenberg Heart and Heart Strategies Concentrating on Risk Eval-
uation (HeartSCORE) study where it was shown to correlate with
conventional risk factors of atherosclerosis and diabetes
[166,167,170,171]. In coronary artery disease, it distinguished high
from moderate and low risk patients [172]. In patients referred to
diagnostic angiography, the calculated score was worse in patients
with coronary artery disease than in patients without [173]; the
score predicted both obstructive and non-obstructive ischemic
heart disease [174]. Similarly to FMD, EndoPAT score is very sensi-
tive in response to risk factors or, conversely, upon initiation of
treatment. (Table 2)
2. Prospective validation and 3. Incremental value: EndoPAT
was predictive of outcomes in 2 studies in heart failure patients
with preserved ejection fraction followed for 5 and 20 months
respectively [175,176]. With respect to primary prevention, there is,
to date, one published study demonstrating the ability to predictfuture CV events during a 7-year follow-up period [177]. In the
aforementioned study, a score (natural logarithmic-scaled reactive
hyperaemia index) < 0.40 was shown to have added prognostic
value after adjustment for the FRS (HR: 1.68; 95% CI: 1.02e2.78)
[177]. (Table 3)
4. Clinical utility: The clinical utility of the method is largely
unknown; no studies have so far examined whether they can
change predicted risk sufﬁciently to change recommended therapy.
5. Clinical outcomes: In a similar fashion to FMD, EndoPAT can
be modiﬁed with drug and lifestyle interventions [178e182].
Nevertheless, it is unclear if such modiﬁcations will eventually
result in a reduction in adverse events; such randomized clinical
trials are awaited.
6. Cost-effectiveness: There are no available data regarding cost-
effectiveness.
7. Ease of use: The method is relatively easy to use, in an
operator-independent manner.
8. Methodological consensus: Measurements are uniformly
performed according to the manufacturer's instructions; never-
theless, guidelines do not exist yet.
9. Reference values: There are no reference values.
Therefore, EndoPAT does not fulﬁll the 9 essential criteria in
order to be considered a clinical surrogate endpoint (Tables 4 and
5).
Advantages/disadvantages, issues remaining to be addressed
and future perspectives:
Endothelial function assessment by ﬁnger recordings is non-
invasive, quick and easy to perform and is both operator and
interpreter-independent. Reproducibility of measurements, mini-
mum training requirements and a strong pathophysiological basis
are ascribed among its advantages. The disadvantages of the
method include the moderate correlation with FMD, which raises
issues regarding the speciﬁcity of the test for endothelial function,
the need for a proprietary device, the cost of single-use ﬁnger
probes, as well as the lack of normal/reference values and of ran-
domized clinical trials addressing prospective validation, incre-
mental value and clinical outcomes issues.
Endothelial function assessment with the EndoPAT method is
not limited by methodological variability, as is the case with FMD,
but it still lacks a solid body of clinical evidence.
Current status in clinical practice guidelines:
Endothelial function assessment by recordings at the ﬁnger is
not endorsed by current guidelines (Table 6).
7. Circulating biomarkers related to vascular wall biology
Usefulness for primary and secondary CV disease prevention
(Recommendation/Level of evidence): IIb/B for high sensitivity C-
reactive protein.
A vast array of biomarkers related to different aspects of CV
pathophysiology has been proposed as candidates for reﬁnement of
risk prediction. The present review focuses on biomarkers that are
related to vascular wall biology; therefore, cardiac troponins and
natriuretic peptides that are the most widely validated and used
biomarkers in clinical practice remain outside its scope. C-reactive
protein (CRP) is, at present, the only circulating biomarker related
to vascular wall biology with a large body of published studies
supporting its clinical use for risk stratiﬁcation. Other novel circu-
lating biomarkers, including oxidized low-density lipoprotein
[183e185] and dysfunctional high-density lipoprotein [186e188],
have a future potential for prevention but are not discussed owing
to their currently limited bench-to-bedside implementation.
High-sensitivity CRP.
High-sensitivity CRP (hsCRP) is a marker of systemic inﬂam-
mation that is up regulated as a consequence of vascular disease
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CRP is present in both atherosclerotic plaques and injured vessel
walls, which are involved in its secretion (small amounts) [190].
Fulﬁlment of surrogate endpoint criteria:
1. Proof of concept: hsCRP levels are correlated to traditional
risk factors, such as systolic BP, lipids and body mass index, as well
as other inﬂammatory indices, such as white cell count,
interleukin-6 (IL-6) and ﬁbrinogen levels.
2. Prospective validation and 3. Incremental value: Amultitude
of studies have examined the predictive potential of CRP above and
beyond classical risk factors (Table 3). In the largest individual data
meta-analysis to date (n ¼ 160,309), the risk ratio for coronary
heart disease per 1-SD higher log(e) CRP concentration (three-fold
higher) was 1.37 (1.27e1.48) when adjusted for age, sex and con-
ventional risk factors [191]. The same study group reported that the
addition of CRP to traditional models for the 10-year risk prediction
improved the C-indexmodestly, yet signiﬁcantly by 0.0039; the NRI
and integrated discrimination index (IDI) were 1.52% and 0.0036
respectively [192].
4. Clinical utility: The clinical utility of CRP, i.e. whether it can
alter predicted risk sufﬁciently to change recommended therapy,
has been tested in a statistical model derived from the aforemen-
tioned meta-analysis. It has been demonstrated that 5.2% of people
>40 years old initially at intermediate CV risk would be reclassiﬁed
in the highest risk category and, thus, be eligible for statin therapy
[193] (Table 3).
5. Clinical outcomes: Regarding clinical outcomes, the Justiﬁ-
cation for the Use of statins in Primary prevention: an Intervention
Trial Evaluating Rosuvastatin (JUPITER) trial reported that using
hsCRP as a goal for statin therapy, even in the absence of dyslipi-
daemia, results in favourable outcomes [194]. Despite receiving
strong criticism, JUPITER reinforced the relationship of inﬂamma-
tory mediation and hard CV endpoints. Results from the ongoing
Cardiovascular Inﬂammation Reduction Trial (CIRT) and Canaki-
numab Anti-Inﬂammatory Thrombosis Outcomes Study (CANTOS)
will further elucidate the effect of targeted anti-inﬂammatory
therapies on CV outcomes.
6. Cost-effectiveness: At present, the cost-effectiveness of
routinelymeasuring hsCRP levels for risk stratiﬁcation has not been
assessed.
7. Ease of use: hsCRP measurement is easy and widely available.
8. Methodological consensus: hsCRP measurement is
standardized.
9. Reference values: A threshold of 2mg/L has been proposed for
CV risk assessment [3]. Nevertheless, a single cut-off value may not
be ideal, because inter- and intraindividual variability exists. This is
attributed to genetic polymorphisms, post-translational mecha-
nisms and presence of comorbidities that can alter baseline values
[189].
Therefore, hsCRP meets some of the 9 essential criteria to clas-
sify as a clinical surrogate endpoint (Tables 4 and 5).
Advantages/disadvantages, issues remaining to be addressed
and future perspectives:
The role of hsCRP for prediction of future CV events is ﬁrmly
established by large trials and meta-analyses. Adoption into clin-
ical practice is facilitated by easy, standardized measurements
using widely available analytical assays. Nevertheless, due to the
fact that this is an acute phase reactant, elevated hsCRP levels lack
speciﬁcity for CV disease. In addition, it is unclear if their rela-
tionship is causal or an epiphenomenon; this is a pertinent
question soon to be elucidated by ongoing studies of anti-
inﬂammatory therapies.
Current status in clinical practice guidelines:
According to the ESC guidelines for CV disease prevention in
clinical practice, hsCRP levels may be measured as part of reﬁnedrisk assessment only in patients with an unusual or moderate risk
proﬁle (class IIb/B recommendation), but not in asymptomatic
low-risk or high-risk individuals (class III/B recommendation)
[24]. The 2010 ACCF/AHA guidelines advocate hsCRP measure-
ment for selecting patients for statin therapy according to the
JUPITER trial inclusion criteria (class IIa/B recommendation), for
risk assessment in asymptomatic men <50 years old/women <60
years old (class IIb/B recommendation), but not in asymptomatic
high-risk adults (class III/B recommendation) [52]. The most
recent ACC/AHA guidelines state that hsCRP measurement may be
considered if, after quantitative risk assessment, a risk-based
treatment decision is uncertain (class IIb/B recommendation) [3].
Regarding dyslipidaemias, the European Society of Cardiology/
European Atherosclerosis Society (ESC/EAS) guidelines do not
recommend measuring hsCRP as a secondary target of therapy for
everybody; however, it may be useful in people close to the high-
risk category to better stratify their total risk [195]. In the recently
published ACC/AHA guidelines for the treatment of blood
cholesterol, a hsCRP level >2 mg/L is an additional factor to be
considered during treatment decision making for individuals
without atherosclerotic disease (class IIb/B recommendation)
[196] (Table 6).
8. Interplay between macro and microvascular disease
Relationships between structural changes in the micro and
macrocirculation
Due to the viscoelastic properties of large arteries, the pulsatile
pressure and ﬂow that result from intermittent ventricular ejection
is smoothed out, so that microvasculature steadily mediates the
delivery of nutrients and oxygen to tissues [197]. The disruption of
this function leads to end-organ damage. Microvascular structure is
not only the site of vascular resistance; it may also substantially
contribute to the wave reﬂections generating increased central
systolic BP in the elderly [197], although the proper location of a
reﬂection site may be elusive [198].
The structure of subcutaneous small resistance arteries, as
assessed by their media/lumen ratio, correlates both with wave
reﬂections, stiffness of large conduit arteries [199] and BP levels; in
a population of more than 200 normotensive subjects and hyper-
tensive patients, clinic systolic, diastolic, mean 24-h systolic and
diastolic BP, as well as the pulse pressure/stroke volume ratio (an
index of large artery compliance) correlated with media/lumen
ratio [200]. Furthermore, it holds a prognostic role, as media/lumen
ratio and pulse pressure (a rough index of large artery stiffness)
were the two most important factors in predicting the outcome of
hypertensive patients [201]. Large artery stiffness is related to ce-
rebral microvascular disease (lacunar infarctions/large white mat-
ter hyperintensities) [202,203]. Using a non-invasive approach
(scanning laser Doppler ﬂowmetry) for the evaluation of retinal
arteriolar morphology, it has been demonstrated that central pulse
pressure and AIx correlate with wall/lumen ratio [204].
Such relationships indicate a coupling and crosstalk between
micro- and macrovascular arterial beds [205]. Increased media/
lumen ratio and rarefaction of capillaries are earlymanifestations of
target organ damage [206], as well as major factors for an increase
in mean BP, which, in turn, increases large artery stiffness through
the loading of stiff components of the arterial wall. The increased
large artery stiffness ampliﬁes pulse pressure, which, subsequently,
damages small arteries of the heart, brain, retina and kidney. Thus,
the crosstalk between small and large arteries exaggerates target
organ damage, following a vicious circle [205].
Studies have demonstrated an improvement or even an almost
complete normalization of the structure of subcutaneous small
resistance arteries with ACE-Is and angiotensin II receptor blockers.
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effects [207].
In conclusion, CV events are the consequence of vascular dam-
age at both the macro and microcirculatory level. The presence of
structural alterations of small resistance arteries may be associated
with the increase in large artery stiffness and possibly contribute to
an increase in central pressure by increasing themagnitude of wave
reﬂections.
9. The role of vascular biomarkers in speciﬁc subgroups
(Table 7)
9.1. Hypertension
9.1.1. Prediction of developing hypertension in normotensive adults
Endothelial dysfunction, as assessed by FMD, has been shown to
provide independent predictive value on the incidence of hyper-
tension [208e210], although these ﬁndings were not always inde-
pendent from baseline BP levels [210].
Of all the herein discussed vascular biomarkers, arterial stiffness
most strongly associates with hypertension. Arterial stiffness is
considered to have a bidirectional causal relationship with BP. On
the one hand, it is proposed that elevated BP has a damaging effect
on the arterial wall thus accelerating the stiffening process; for that
reason high PWV is regarded as BP-related target organ damage. On
the other hand, arterial stiffening is regarded as the principal cause
of increased systolic BP in the elderly. The later hypothesis is now
supported from 8 prospective epidemiological studies including
collectively over 18,200 individuals ranging 30e80 years of age
[209,211e214]. All these studies, independently from the method
that was used to assess arterial stiffness (local carotid elasticity by
ultrasound [211], aortic stiffness by ultrasound [212] or magnetic
resonance imaging [215], baPWV [213,214,216] or cfPWV [209,217],
small artery elasticity determined by pulse contour analysis [215]),
showed that arterial stiffness can predict the incidence of hyper-
tension independently from baseline BP level and age. The increase
in the risk for future development of hypertension ranged from 15%
[211] to 30% [209] per 1-SD increase in arterial stiffness, or 10% per
1 m/s increase in PWV [217]. So far there are no established cfPWV
cut-off values in order to recommend more intense prevention
strategies in individuals at high risk to develop hypertension. One
study indicated the cut-off of 5.8 m/s for cfPWV [217], which clearly
depends on the population's age and the applied methodology,
whereas a cut-off value around 13 m/s for baPWV has been indi-
cated by two studies [214,216]. Speciﬁcally designed trials are
warranted; it should be noted that the aforementioned values refer
to the predictive ability of cfPWV and baPWV for subsequent
development of hypertension and not CV event prediction.
Scarce data on the ability of other vascular biomarkers to predict
the incidence of hypertension exist for wave reﬂections [209], and
cIMT [215]. Of note, one study showed that cfPWV, AIx and FMD
predicted the incidence of hypertension independently of each
other [209]. Very limited negative evidence exists regarding the
ability of CRP to predict the development of hypertension [216].
9.1.2. CV risk stratiﬁcation in hypertensive individuals
The ESH/ESC guidelines for the management of arterial hyper-
tension encourage the screening for asymptomatic organ damage
as an intermediate stage in the continuum of vascular disease [23].
So far, among all vascular biomarkers, FMD is the only one
supported by a clinical study (although non-randomized) showing
that endothelial function improvement with antihypertensive drug
treatment is associated with a reduction in events in hypertensive
postmenopausal women [158]. However, no speciﬁc data exist on
the ability of FMD to reclassify CV risk in hypertensives.Regarding arterial stiffness, the ESH/ESC guidelines for the
management of arterial hypertension focus on the gold-standard
index, the cfPWV, suggesting that a cut-off value above 10 m/s
(when the distance is assessed as 80% of the direct distance) should
be considered as evidence of subclinical organ damage [23]. Three
cohorts with hypertensive individuals (total 3300 persons) pro-
vided data on the independent predictive ability of cfPWV [81,218]
and baPWV [219] for all-cause mortality and CV events/mortality.
Of note, the predictive ability of cfPWV in hypertension is valid
throughout the whole age range [89], which is not the case for
other speciﬁc pathologies, such as end-stage renal disease. How-
ever, although in one subanalysis the ability of cfPWV to predict
primary coronary artery disease events above the FRS was shown
[80], no study so far has addressed the speciﬁc issues of discrimi-
nation and/or reclassiﬁcation in hypertension. It is advisable that
the reclassiﬁcation data (15%e19%) [91,92] that are derived from
general population studies (approximately 30% of the study pop-
ulation were hypertensives with no other risk factors) or other
selected populations, should be cautiously extrapolated to in-
dividuals with essential hypertension. The most recent individual-
data meta-analysis on the ability of cfPWV to predict mortality and
CV events showed that there is no difference between individuals
with and without hypertension; the same study showed an overall
13% reclassiﬁcation [88]. The treatment beneﬁt for hypertensives
after risk reclassiﬁcation by cfPWV remains open to question. The
selection of most appropriate BP lowering drugs with more
established “de-stiffening” properties is reasonable, but data on
earlier drug treatment initiation, more aggressive BP lowering or
addition of other major CV risk prevention drugs (statins and/or
aspirin) are not available.
Regarding the ability of wave reﬂections and central haemo-
dynamics to reclassify CV risk in hypertensives, the data are het-
erogeneous and limited; a recent a meta-analysis included all the
available data from a variety of high risk populations [131]. How-
ever, in terms of clinical utility, one cannot neglect the fact that
different classes of antihypertensive drugs have variable effects on
wave reﬂections and central BP that are accompanied with target
organ damage regression [134,135]; these effects cannot be always
monitored from the brachial pressure or anticipated by arterial
stiffness that may remain unchanged [129,220]. Indirect evidence
on the clinical value of this fact was provided by the CAFE study,
where, despite a similar reduction in peripheral systolic BP, a
calcium-channel blocker regimen was more effective in lowering
central systolic BP and reduced future CV events compared with a
beta-blocker regimen [129]. In the aforementioned study, excess
pressure integral (XSPI), a novel central haemodynamic index,
predicted outcomes independently from traditional risk scores and
the FRS [221].
Whether cIMT and/or the presence of carotid plaque reclassify
hypertensives in a clinically meaningful way is still debated.
Recently, in the hypertensive subgroup of the USE-IMT individual
data meta-analysis, common cIMT measurements did not show
added value. Nevertheless, when only hypertensives at interme-
diate risk were examined, the addition of cIMT to existing risk
scores determined a small, yet signiﬁcant improvement in reclas-
siﬁcation (NRI: 5.6%) [222]. The European Lacidipine Study on
Atherosclerosis (ELSA) failed to show a predictive role of treatment-
dependent cIMT changes in treated hypertensives, despite the
added predictive role of baseline cIMT values and plaques [223].
The ability of ABI to reclassify CV risk in hypertension has not
been addressed in speciﬁc cohorts of hypertensive individuals.
However, an analysis of the National Health and Nutrition Exami-
nation Survey (NHANES) cohort which is comprised by almost 75%
hypertensives, suggested that in CV disease-free individuals with
ABI<0.9, better outcomes were observed in those whowere at least
Table 7
The role of vascular biomarkers in patients with comorbidities.
Hypertension Dyslipidaemia Diabetes
mellitus
Peripheral
arterial disease
Stroke Renal disease Coronary
artery disease
Carotid ultrasonography þþ (for intermediate
risk individuals)
þþþ þþ þþ þþþ þþ þ
Ankle-brachial index þþþþ þþþ þþþ þþþþ þþþ þþ/þþþ þþþ
Arterial stiffness
Carotid-femoral pulse wave velocity þþþþ þþ þþ or þþþ þþ þþþþ þþþþ þ
Brachial-ankle pulse wave velocity þþþþ þþ þþ Non applicable þþ þþþ þ
Central haemodynamics/Wave reﬂections þþ þ þþ þþ þþ þþ þþþ
Endothelial function
Flow mediated dilatation þ þþ þ þ þ þ þþ
Endothelial peripheral arterial tonometry þ þ þ e e e þþ
Circulating biomarkers related to vascular wall biology
High sensitivity C- reactive protein þ þþþ þ þ þ þþ e
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agents, ACE-I/angiotensin receptors blockers and/or statins) [67].
The impact of ABI-driven therapeutic decisions in hypertensives
warrants further investigation.
In conclusion, “primordial prevention” (i.e. avoidance of ever-
having risk factors) and maintenance of low risk (maintaining
optimal risk levels throughout life) are now promoted. The limited
data derived from studies in hypertension and extrapolation of data
from the general population show that cfPWV can reclassify CV risk
substantially and predict the development of hypertension inde-
pendently of baseline BP levels and other risk factors. Future
studies should focus on lifestyle changes and assess whether these
interventions can delay arterial stiffening and progression to hy-
pertension. Carotid ultrasound has additive value in intermediate-
risk hypertensives, especially when either an increased cIMTand/or
the presence of plaque are sought for. Based on the limited number
of studies, ABI may also have additive value in CV risk stratiﬁcation.
Implementation of vascular biomarkers is most useful in risk
stratiﬁcation among patients at intermediate risk. More studies
assessing the additive value of vascular biomarkers to traditional
risk factors and outcome studies with vascular biomarker-driven
therapy are needed.
9.2. Diabetes mellitus
9.2.1. Prediction of developing diabetes mellitus in diabetes-free
individuals
Microvascular dysfunction has been proposed as a potential
mechanism leading to insulin resistance and type 2 diabetes melli-
tus, because it impairs the timely access of glucose and insulin to
their target tissues. This hypothesis was further conﬁrmed by a
meta-analysis showing that dysfunction of the microcirculation, as
assessed by various circulating and vascular biomarkers (which are
beyond the scope of thismanuscript) is an independent determinant
of incident diabetes mellitus [224]. On the other hand, the hypoth-
esis of the CV continuum in diabetes suggests that alterations/
dysfunction of macrocirculation take place early in the course of
glucometabolic impairment, before the clinical onset of type 2 dia-
betes mellitus [70]. One step further, it was recently shown that the
presence of carotid plaques is a predictor of incident diabetes inde-
pendently of the metabolic proﬁle, BP and related drugs [225].
9.2.2. CV risk stratiﬁcation in patients with diabetes
Relatively limited studies have addressed the ability of the
herein discussed vascular biomarkers to reclassify CV risk in dia-
betic populations.
Data derived from a meta-analysis of 4220 individuals with
diabetes showed that there was no NRI with the addition of mean
common cIMT to the FRS, suggesting that cIMT should not berecommended for improving CV risk stratiﬁcation in individuals
with diabetes [34]. Data on carotid plaque NRI are not available.
One study so far suggests that cfPWV is a robust independent
biomarker that integrates and predicts mortality in diabetes [77].
Local stiffness indices at the carotid, femoral and brachial artery
may provide additional mutually independent information on
incident all-cause mortality and events [72]. Due to sample size
limitations, no data on the reclassiﬁcation ability of arterial stiffness
biomarkers are available from these two studies; however, no dif-
ferences between non-diabetics and diabetics have been found,
thus favoring the extrapolation of data from non-diabetic pop-
ulations [72].
Although concerns about the validity of the cut-off of 0.90, as
well as the association between the ABI andmortality in individuals
with diabetes have been raised, new evidence show that low ABI
has similar clinical value in individuals without and with diabetes
[226]. However, the use of aspirin or antioxidants for the primary
prevention of CV events/mortality in diabetics with an ABI <1.0 is
not justiﬁed [66]. Studies on statins or other CV reduction strategies
are not available.
Medial calcinosis and its consequence, a high (>1.40) ABI is
frequent in long-standing diabetes [58]. This condition is associated
with increased risk of mortality but only when occlusive PAD co-
exists. The latter should be diagnosed with further investigations in
case of high ABI (e.g. toe-brachial index or Doppler waveform
analysis) [59,60,227]. In a recent report, high ABI was associated
with increased risk of CV mortality only in diabetic patients, where
toe-brachial index was mostly decreased, underlining the high
frequency of occlusive PAD concealed by the medial calcinosis
during the ABI measurement.
9.3. Dyslipidaemia
9.3.1. Prediction of developing dyslipidaemia in individuals with
normal lipid proﬁle
There are no studies supporting the ability of vascular bio-
markers to predict the future development of dyslipidaemia.
9.3.2. CV risk stratiﬁcation in individuals with dyslipidaemia
The European guidelines for the management of dyslipidaemias
suggest the use of cIMTand/or plaque presence for risk stratiﬁcation,
in order to better deﬁne the optimal LDL treatment target [195].
Although this is a reasonable approach, since cIMT and particularly
plaque presence indicate the presence of atherosclerosis, no data
exist for the ability of cIMT/plaque to reclassify CV risk in individuals
with dyslipidaemia. Moreover, the potential clinical value of cIMT/
plaque to stratify risk within the population of familial hyper-
cholesterolaemia remains uncertain; however, its use may be
reasonable since risk within this group is highly variable [228]. To
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risk reclassiﬁcation in individuals with dyslipidaemia.
9.4. Peripheral artery disease
The presence of PAD stratiﬁes patients among the highest risk
groups. Compared with people of the same age, patients with PAD
have a signiﬁcant higher percentage of risk factors and, thus, a
higher CV risk [229]. Symptomatic PAD is associated with a 2- to 8-
fold increase in severe CV events and nearly a fourfold increase of
mortality [230,231]. CV risk in PAD patients is even more increased
in the setting of polyvascular disease. The risk for CV death,
myocardial infarction, stroke and hospitalisation is approximately
12% with 1 vascular bed disease and approximately 26% with 3
vascular bed disease [232]. The importance and implications of
non-coronary atherosclerosis (i.e. PAD of upper and lower ex-
tremities, carotid arteries, thoracic/abdominal aorta, mesenteric
and renal arteries) has been scrutinized in a review by the ESC
Working Group on Peripheral Circulation [233].
The use of vascular biomarkers may further reﬁne risk stratiﬁ-
cation for PAD patients. FMD has shown an independent predictive
ability for CV events in PAD patients. In addition, patients with PAD
and relatively normal endothelial function have a very low risk of
events and this holds true for long-term follow up periods
[223,234].
Currently, data regarding the predictive ability of PWV and
EndoPAT for CV events in PADpatients are lacking. This is also true for
cIMT; numerous dedicated trials underline the relationship of
increasedcIMTwithreinterventionordiseaseprogressionatdifferent
sites, but not its predictive ability for CV events in PAD [235].
ABI has an outstanding position not only as a diagnostic but also
as a prognostic tool in PAD patients without medial calcinosis.
Details regarding the predictive role of ABI in PAD patients are
provided in the respective section of the document above.
Concerning circulating biomarkers, CRP predicts disease pro-
gression and long-term CV mortality. Patients with intermittent
claudication and elevated high sensitivity CRP levels hadmore than
5 times higher risk for CV mortality than those with low levels of
this inﬂammatory biomarker (HR: 5.16; 95% CI 1.78e14.8) [236].
9.5. Stroke
Stroke seems to be an equally robust biomarker as PAD is for
prediction of CV events and death. A history of cerebrovascular
disease is associated with an HR of 1.42 for further events [237].
Concerning risk, this is not substantially different between so called
low risk patients with a non-recent transient ischaemic attack,
patients with a stroke at a young age or patients with a stroke at an
older age. For stroke patients, impaired FMD proved to be an in-
dependent predictor for new onset of general vascular events (HR:
3.48; 95% CI: 1.26e9.63) [238]. In stroke patients, common cIMT
predicted stroke recurrence; for each 0.1 mm increase, the proba-
bility of recurrent stroke increased by 18% (CI: 2.0%e36%) in a
follow-up period of 28.9 months [239]; this is also the case for ABI
[35,234,240] Baseline cfPWV values have a predictive role
regarding functional outcomes of stroke patients [68,87].
9.6. Renal impairment
Renal impairment is also considered as target organ damage of
atherosclerotic disease and, when adjusted to the different grades
of impairment, CV risk can be very well predicted [241]. As esti-
mated glomerular ﬁltration rate declines, the risk for CV events
increases. This is particularly true in patients with PAD, where renal
dysfunction predicts long-term mortality [242]. Studies in patientswith chronic kidney disease [93] and end-stage renal failure [83]
have shown that cfPWV can further stratify cardiovascular risk in
the presence of renal impairment. Data on ability of PWV to
reclassify cardiovascular risk in these populations are missing but
the most recent individual data based meta-analysis on the ability
of cfPWV to predict mortality and CV events showed that there is
no difference regarding the ability of cfPWV to associate with
outcomes between individuals with and without impaired renal
function (stage 0e5) [88].
10. Pharmacological modiﬁcation of vascular biomarkers and
CV risk
Different drug classes, as well as non-pharmacological ap-
proaches, can alter measured levels of vascular biomarkers.
(Table 8) The pertinent question is whether this modiﬁcation will
translate in a subsequent reduction of morbidity and mortality. The
dal-HEART program constitutes an insightful example of the use of
vascular biomarkers as surrogate endpoints in clinical trials. Dal-
cetrapib, a cholesterol ester transfer protein (CETP) inhibitor, raised
HDL levels but failed to improve endothelial function (assessed by
FMD) and marginally improved carotid artery remodelling in pa-
tients with, or at high risk for CAD [243,244]. In concordance with
the lack of effect on vascular biomarkers, dalcetrapib did not reduce
the risk of recurrent CV events [245]. A similar failure of torcetrapib
to decrease the progression of carotid and coronary atherosclerosis
was accompanied by increased morbidity and mortality [246,247].
Pharmacological modulation of endothelial function:
Thiazide and thiazide-like diuretics do not have an effect on
endothelial function; aldosterone antagonists have a beneﬁcial ef-
fect in the setting of hypertension but not in type 2 diabetes mel-
litus [248e250]. ACE-I and angiotensin receptor blockers improve
endothelial function. A differential effect on endothelial function in
the macro- and microcirculation has been found for some antihy-
pertensive drugs: calcium channel blockers improve endothelial
function at the microcirculatory level, while the effect on the
macrocirculation is not convincing. The opposite was seen for
vasodilating beta-blockers like nebivolol: an improved endothelial
function mainly at the macrocirculatory level, but not convincing at
the microcirculation [251]. A meta-analysis including 25 random-
ized controlled trials conﬁrmed the favorable effect of ACE-I on
endothelial function measured with brachial FMD, which did not
differ from angiotensin receptor blockers but was superior to the
effect of calcium channel blockers and beta-blockers [252]. Non-
vasodilating beta-blockers have no effect on endothelial function.
In contrast, the third generation beta-blockers nebivolol and car-
vedilol have a beneﬁcial effect on endothelial function through
preservation of NO synthase activity by reducing asymmetrical
dimethylarginine and by enhancing the bioavailability of NO
because of their antioxidant properties. In addition, nebivolol ac-
tivates NO synthase [253]. In a similar fashion, other drugs like
phosphodiesterase type 5 inhibitors [254], statins [255e257] and
thiazolidinediones, such as pioglitazone [258], improve endothelial
function.
Pharmacological modulation of arterial stiffness:
The large majority of antihypertensive drugs decrease arterial
stiffness [74,259e261]. However, it is not always clear whether this
decrease in stiffness is limited to a ‘passive’ decrease induced by a
lower BP, or whether the drug has an additional active effect on the
stiffness of the vessel wall. Despite the decrease in BP, a substantial
amount of studies with diuretics and nonselective beta-blockers
did not show a decrease in arterial stiffness. In comparative
studies, for a similar decrease in BP, ACE-I had a larger effect on
arterial stiffness than calcium channel blockers [262] and the
combined diuretic amiloride-hydrochlorothiazide [263],
Table 8
Pharmacological modiﬁcation of vascular biomarkers.
Carotid intima-media
thickness
Arterial stiffness Central systolic
blood pressure
Wave
reﬂections
(augmentation
index)
Endothelial function
Angiotensin-converting
enzyme inhibitors
Y Y cSBP > pSBP YY þa
Angiotensin receptor
blockers
Y Y cSBP > pSBP/
cSBP ¼ pSBP
Y þ/
Direct renin inhibitors Y Y cSBP > pSBP Y þ
Aldosterone antagonists Y Y/- cSBP ¼ pSBP Y þ
Calcium channel blockers YY (more pronounced
effect may be due to
larger vasodilation)
Y cSBP > pSBP/
cSBP ¼ pSBP
YY þb
Diuretics Y Y/- cSBP < pSBP/
cSBP ¼ pSBP
e e
NO donors Y
Nitrates Y/ cSBP > pSBP Y
b-blockers Y Y (non-vasodilating);
YY (vasodilating)
cSBP < pSBP
(non-vasodilating);
cSBP > pSBP
(vasodilating,
mainly nebivolol)
[ (non-vasodilating);
[//Y (vasodilating)
±/c (non-vasodilating); þa
(vasodilating,
mainly nebivolol)
a-blockers Y Y
Centrally acting
drugs (moxonidine)
e cSBP ¼ pSBP e e
Phosphodiesterase-5
inhibitors
Y (short-term effect) trend for
cSBP > pSBP
Y þ
Statins Y/ Y (ezetimibe has
a similar effect)
cSBP ¼ pSBP Y þ
Anti-tumor necrosis
factor a (TNFa)
Y þ
Advanced glycation
end (AGE)
product breakers
Y
Thiazolidinediones Y Y þ
For endothelial function: ±: weak beneﬁcial effect; þ: beneﬁcial effect; : neutral effect.
For arterial stiffness, all effects are long-term effects (1 month), unless indicated otherwise; Y: decreases arterial stiffness; : neutral effect.
For wave reﬂections (augmentation index): Y: decrease; : neutral effect; [: increase.
For central systolic blood pressure the effect on central systolic blood pressure (cSBP) beyond the effect on peripheral systolic blood pressure (pSBP) is examined; cSBP > pSBP:
a more pronounced effect on cSBP compared with pSBP; cSBP ¼ pSBP: similar effect on cSBP and pSBP; cSBP < pSBP: a smaller effect on cSBP compared with pSBP.
For cIMT: Y: decreases IMT; : neutral effect.
a More pronounced effect on macrocirculation.
b More pronounced effect on microcirculation.
c Neutral effect for atenolol, weak beneﬁcial effect for metoprolol.
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In short-term trials, arterial stiffness can be improved by func-
tional changes (vascular smooth muscle relaxation) and to some
extent also by structural changes. Strong vasorelaxation, as can be
seen with some nitrates, however, can lead to an increase in
diameter and arterial compliance without changing arterial stiff-
ness. In long-term trials with antihypertensive drugs, structural
changes are likely to be more prominently present [262,264]. In
long term trials, calcium channel blockers, beta-blockers and di-
uretics improved arterial stiffness also after adjustment for mean
BP, heart rate, gender and other CV risk factors [262], suggesting
that a sustained decrease in BP per se may improve arterial stiff-
ness. Also, in this long term study ACE-I tended to be the most
effective, suggesting a direct BP independent effect of this drug
class on arterial wall remodeling. Similar destiffening effects have
been reported after long-term treatment with olmesartan, sug-
gesting that renin-angiotensin system blockade, either by ACE-Is or
ARBs, exerts beneﬁcial effects on arterial stiffness [265]. Meta-
analytical approaches have attempted to identify differential
effectiveness of classes of drugs but results are inconclusive due to
small number of studies [266].
Anti-inﬂammatory drugs (corticoids, anti-tumor necrosis factor
agents), lipid lowering drugs (statins, ezetimibe) and phosphodi-
esterase type 5 inhibitors [254,267] can decrease arterial stiffness.This potential has also been demonstrated by some NO donors,
antidiabetics (thiazolidinediones) and advanced glycation end
product inhibitors/breakers [74,268]. However, these drugs are
currently not on the market or not advised to be used as ﬁrst-line
drugs due to major side effects.
Pharmacological modulation of central systolic blood pres-
sure and wave reﬂection:
Amore pronounced decrease in central BP beyond peripheral BP
has been observed in a majority of studies with inhibitors of the
renin-angiotensin system (ACE-I, angiotensin receptor blockers and
direct renin inhibitors), calcium channel blockers nitrates and
phosphodiesterase type 5 inhibitors. The opposite was found with
beta-blockers, while diuretics appear to be rather neutral
[220,254,267,269e271]. Wave reﬂections measured by AIx were
decreased by renin-angiotensin system blockers, calcium channel
blockers, nitrates, phosphodiesterase type 5 inhibitors and aldo-
sterone antagonists, while other diuretics did not change AIx
[260,261,267,272]. In contrast, a majority of studies with non-
vasodilating beta-blockers showed an increase in wave reﬂection,
while vasodilating beta-blockers did not change or decreased AIx
[260,273]. Other vasodilating drugs and statins may have a bene-
ﬁcial effect on central systolic BP and wave reﬂections [268].
Pharmacological modulation of cIMT and carotid plaque:
A meta-analysis of 22 randomized clinical trials on the effect of
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blockers, calcium channel blockers, angiotensin receptor blockers
and alpha blockers, showed the superiority of calcium channel
blockers over other classes of antihypertensive drugs in reducing
cIMT [274]. However, it cannot be sure that the larger reduction in
cIMT also represents a larger reduction in intima-media wall mass.
Indeed, the reduction in cIMT was also associated with a larger
carotid artery diameter. It has been shown that the larger systolic
carotid diameter is accompanied with a decrease in cIMT of about
25 mmversus diastolic cIMT [275]. Since no cross-sectional IMTarea
has been measured, it cannot be excluded that the larger decrease
in cIMT and superiority of calcium channel blockers may not
represent a real decrease in intima media mass. Apart from anti-
hypertensive drugs, statins have been shown to reduce cIMT in
patients with familial hypercholesterolaemia [255] and dyslipi-
daemia in general [276]. Nevertheless, some studies failed to show
a decrease in cIMT after a 6-month treatment with statins
[257,277]. Whether a more prolonged statin treatment might lead
to a reduction in cIMT is not clear.
Interventions to reduce total plaque area or volume seem to
promise success, since the concept of stabilizing the vulnerable
plaquemay be associatedwith a reduction of plaque volume and/or
area. However, only small and limited numbers of studies are
currently available and are not sufﬁciently reproduced by inde-
pendent groups [278]. This may change if easy applicable 3D ul-
trasound will be used more often in the future, based on recent
technical progress in 3D imaging [279].
A summary of the effect of drugs on vascular biomarkers is
presented in Table 8.
Effect of lifestyle changes:
Lifestyle modiﬁcation can have a positive impact on vascular
biomarkers. Weight reduction improves endothelial function [280]
and lowers CRP [281], oxLDL [282], cIMT [283], wave reﬂections
and arterial stiffness [284], especially when combined with exer-
cise [285e287], but does not inﬂuence ABI values [288]. Endurance
exercise leads to improved central haemodynamics [289] and
endothelial function [290]; the effect of high-intensity resistance
training on arterial stiffness is detrimental [290]. Beneﬁcial effects
have been reported following smoking cessation [162].
Effect of food supplements:
Apart from lifestyle changes, different foods and food supple-
ments have shown a beneﬁcial effect on endothelial function: an-
tioxidants like vitamins C and E, ﬂavanols and polyphenols (cocoa,
tea, redwine, beer), lycopene (tomatopaste), grape fruit extracts and
omega-3 fatty acids [251,291e294]. Some food supplements like
cocoa result in decreased levels of aortic stiffness, wave reﬂections
and central systolic BP [295]. Caffeine increases central BPs to a
greater extent than peripheral BPs, as well as arterial stiffness [296].
11. Conclusion
Biomarkers should not be routinely measured during the CV risk
evaluation of all patients [3,24]; this role is reserved for risk scores
[4,297]. However, the addition of a vascular biomarker tends to add
only modestly, yet signiﬁcantly beyond classical risk factors and
may be particularly useful in those patients classiﬁed as having
intermediate CV risk and in whom there is a therapeutic dilemma
[240]. The higher values of clinical NRIs, as opposed to overall NRIs,
in studies and meta-analyses highlight the utility of biomarkers in
those patients. Risk reﬁnement, i.e. reclassiﬁcation in a higher/
lower risk stratum and relevant therapeutic decisions can be made
by measuring one or more biomarkers. In those cases that mea-
surement of biomarker is deemed useful, biomarkers related to the
vasculature are an attractive choice since they integrate, predict
risk and detect subclinical disease from different vascular beds.The increasing number of vascular biomarkers provides com-
plementary information that facilitates the assessment of structure,
function and metabolism of arteries; such information can serve as
a proxy for CV disease upon fulﬁllment of criteria (Tables 1 and 4).
On the basis of these criteria, vascular biomarkers can be classiﬁed
in three groups:
1. Those that fulﬁll most of the 9 essential criteria and, therefore,
are close to being considered a clinical surrogate endpoint (ca-
rotid ultrasonography, ABI, cfPWV).
2. Those that fulﬁll some, but not all of the 9 essential criteria
(baPWV, central haemodynamics/wave reﬂections, hsCRP) and
3. Those that do not at present fulﬁll the 9 essential criteria (FMD,
EndoPAT) (Table 5).
Nevertheless, at this point, it is unclear if a speciﬁc vascular
biomarker is overly superior. This would require a study in which
all vascular biomarkers would have been measured; indirect evi-
dence can be deducted from large studies and meta-analyses
[35,227,234,298]. (Table 3) In selected cases, the combined
assessment of more than one biomarker may be required [149,299].
Instead of the “one size ﬁts all” approach, it is evident that vascular
biomarkers have different strengths (Table 2) and choice may be
dictated by the clinical setting and present comorbidities (Table 7).
The ideal vascular biomarker may be different for each patient and
should be further explored. Importantly, the promise of vascular
biomarker-driven therapeutic decisions should be validated
through randomized clinical trials data.
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